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The main purpose of practical training is acquiring by a physician basic 
working knowledge in the in-patient clinic and achieving basic competence in the 
leading spheres of clinical practice – ability to solve typical professional tasks 
(organizational, diagnostic and treatment, including emergency care). 
 
Tasks of practical training in Internal medicine 
1. The students should master: 
 examination of patients with the most common therapeutic diseases; 
 evaluation of data of the medical interview and examination of the patient; 
 formulation of initial diagnosis; 
 planning of additional investigations; 
 monitoring the dynamics of the patient’s condition and reflecting daily 
observations in diaries; 
 correction of management plan according to the dynamics of the patient’s 
condition under the physician’s supervision; 
 providing immediate and long-term prognosis; 
 making recommendations for the case management at the out-patient unit; 
 appropriate keeping of medical records; 
 delivery of healthcare in emergency according to modern protocols. 
2. The student should be familiar with: 
 order of prescription, storage, drug inventory and administration of 
medications (especially of potent ones and drugs); 
 work of physiotherapy department; 
 work of functional diagnostics department and laboratory; 
 work of department of morbid anatomy. 
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Structure of practical training 
On-the-job training of a medical student “physician’s in the hospital” is 
conducted in the 4th year of study during training course in internal medicine. 
Overall practice time is 45 academic hours. A student works as a doctor’s assistant 
(subordinator) at a therapeutic department of a hospital. Under the supervision of 
the staff physician the student follows-up patients. The student is under the 
command of the physician-supervisor, head of the therapeutic department and 
practice supervisor (assistant professor of the Internal Medicine Department). 
The beginning of practice is synchronous with the beginning of training 
course “Internal Medicine: Module 1”. On the first day of practical training 
students have to come to the department of Internal Medicine to be distributed in 
the therapeutic departments of the hospital, where practical training will take place 
and undergo initial safety training on the organization of the hospital’s work. 
Working day at the therapeutic department starts at 8:30 am. 
Beginning with the first day of practical training the student keeps records in 
a diary (appendix 1), which reflects all kinds of activities performed during the 
day. Among these obligations are: 
 participation in morning organization briefings; 
 participation in pathologic and clinical conferences; 
 work with patients in wards and filling in observation diaries; 
 initial examination of patients with the physician-supervisor and formulation 
of initial diagnosis; 
 planning additional investigations of the patient; 
 defining case management tactics and making management plan by choosing 
adequate pharmacological and physical therapy; 
 maintenance of patient’s medical records; 
 direct participation in diagnostic and therapeutic manipulations. The level of 
mastering of these manipulations is recorded in student’s individual plan of 
practical training.  
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Responsibilities of the direct supervisor 
(Head of Therapeutic Department) 
1. Admits student at the training base, notes the date of arrival and departure, 
takes attendance of the student in the record. 
2. Enables the student to master practical skills according to the individual plan 
and approved list. 
3. On completion of practical training certifies documents (see the list of 
required documents) by the signature and personal stamp. 
 
Responsibilities of the supervisor of practical training 
1. Submits direction for practical training of students to healthcare facility 
(HCF). 
2. Provides students' arriving to HCF, distributes them to departments and 
provides initial safety training. 
3. Provides collaboration with direct supervisor on organization of practical 
training and gives the student all necessary educational learning materials. 
4. Organizes providing students with all educational materials (textbook, 
example of diary maintenance, a list of necessary skills and requirements for 
evaluation of practical training by criteria "reviewed", "acquired", "mastered"). 
5. Controls workplace discipline during the course of practical training. 
6. Consults the students on all issues of practical training. 
7. At the beginning of academic classes controls the adequacy of the diary 
maintenance and the level of practical skills mastering. 
8. Participates in the final control. Records all information on attendance of 
practical training, current, final and total scores, received by the student during 
practical training in the log. 
9. Submits the report and proposals as for practical training to the person 
responsible for practical training. 
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Responsibilities of the person, liable for practical training 
1. Provides registration of contractual relationships with the head of HCF. 
2. Fills in passports of practical training bases. The passports include personal 
data of supervisors, department capacity, technical possibilities for mastering 
practical skills according to the program and maximum number of students which 
clinical base can admit simultaneously. 
3. Executes direction of students to HCF, conducting practical training. 
4. Controls the work of supervisors from the Internal Medicine Department. 
5. Controls methodical support of supervisors and students. 
6. Controls filling in summary information of students’ evaluation in the log. 
7. Submits the report on traineeship to the department in charge of practical 
training of every faculty (attendance, workplace discipline, evaluation).  
8. Submits propositions on optimization of traineeship to the department in 
charge of practical training.  
 
Instructions for filling in individual student's plan of practical skills 
At the end of the practical training the evaluation of the level of practical 
skills mastering is performed. Results of evaluation are recorded into the 
“Individual student's plan of practical skills”. The list of necessary practical skills 
and three degrees of its mastering (“reviewed”, “acquired” and “mastered”) are 
arranged in the relevant sections of the tables. 
The level “reviewed” – the student has theoretical understanding of the 
methodology of manipulations performance and/or was present during its 
performance, but can’t carry out the procedure(s) without assistance, or performs it 
with gross mistakes. 
The level “acquired” – the student has theoretical understanding of the 
methodology of manipulations performance and/or was present during its 
performance and directly took part in carrying out of the latter, but makes mistakes 
in methodology or interpretation of results, if it is a diagnostic manipulation. 
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The level “mastered” – the student has theoretical understanding of the 
methodology of manipulations performance and/or attended the manipulation; 
mastered the method of performing and interpretation of the results and is able to 
perform the skill on his/her own. 
A mark is to be written in the appropriate column according to the level of 
practical skills handling, date of the exam, and signature of the immediate 
supervisor or supervisor of the practical training. 
 
The main documents to be completed during the practical training 
1. The direction card to traineeship, which indicates the start and end date of 
practical training. The immediate supervisor signs the card and certifies it with a 
personal stamp. 
2. The practice diary with signatures and stamps of the direct supervisor. 
3. “Individual student’s plan of practical skills” with the signature of the 
supervisor of practical training. 
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METHODOLOGICAL INSTRUCTIONS ON MAINTENANCE OF 
MEDICAL RECORDS IN THE HOSPITAL  
 
During the course of practical training, the student should get the basic skills 
on keeping of medical records. The main documents for assimilation are: 
1. Medical record of the in-patient department. 
2. Case record of the out-patient (of the in-patient) department. 
 
MEDICAL RECORD OF THE IN-PATIENT DEPARTMENT 
The most important document is the Medical Record of the in-patient 
department. It includes medical case history, medication administration record 
(MAR), temperature sheet, statistical card and discharge summary. The following 
algorithm of actions with case history is provided to acquire practical skills in 
correct quick examination of the patient, formulation of preliminary diagnosis and 
drawing up of examination and treatment plan. 
 Stage I: personal data and the data necessary for record keeping on 
patient’s transfers within a hospital and statistical processing of data (to be filled in 
on the front page of the patient’s case history). 
 It is necessary to clear up the following information: 
 patient’s first name and last name; 
 date of birth; 
 gender; 
 height and weight; 
 place of work with full name, occupation; it is needed to fill in sick-leave; 
 address of the permanent residence, phone number; 
 that who referred the patient to the hospital, date of initial reference to a 
doctor; 
 diagnosis, made in the institution that referred the patient to the hospital. 
Also, on the front page the following information should be presented: 
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 diagnosis on hospitalization; 
 clinical diagnosis made not later than on the third day of hospital stay; 
 final clinical diagnosis, that is cleared up on discharge of the patient from 
the hospital; 
 date and time of admission and discharge from the hospital or death; 
 presence of drug allergy; 
 number of the sick-leave; 
 total number of days of hospital staying. 
 
Stage II: Initial examination of the patient 
Initial examination of the patient is performed by the generally accepted algorithm: 
 
MEDICAL INTERVIEW 
 taking patient’s complaints with obligatory detailing; 
 history taking; 
 patient’s life history with a focus on the facts that can impact on the disease 
directly or indirectly; 
 allergic history. It is very necessary to pay attention to the presence of drug 
allergy. 
 
EXAMINATION 
 state of consciousness; 
 the patient's position; 
 constitutional type; 
 condition of the skin and visible mucous membranes (color, moisture, 
presence of damage, skin tightness, edemas, state of the superficial veins, 
dermographism); 
 condition of the subcutaneous fat; 
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 face (symmetry, changes of the eyes, presence of damages, developmental 
defects); 
 mouth (changes of the tongue, teeth, peripharyngeal ring); 
 neck (deformations, thyroid gland changes); 
 condition of the joints (presence of deformations, the range of motions); 
 respiratory rate, distance wheezing, involving of additional musculature in 
respiration, synchronic work of the chest during respiration; 
 form of the chest (normosthenic, asthenic, hypersthenic, pathological 
changes); 
 spinal column (physiological bends, abnormal curvature); 
 anterior abdominal wall (shape, size, presence of hernias, visible pulsations 
and/or peristalsis, postoperative scars); 
 groin area (presence of hernias, changes from the side of genitals); 
 presence of abnormal motion activity; 
 determining skin reflexes and skin sensitivity; 
 
PALPATION 
 skin (moisture, skin tightness, edemas, temperature, dermographism); 
 lymphatic glands;  
 thyroid gland; 
 thorax (pain on palpation, resistance, apical beat, voice tremor); 
 pulse (rate, power, resistance, tension, uniformity on both arms); 
 anterior abdominal wall (surface palpation to determine tension and / or 
pain, deep palpation with defining specific symptoms); 
 joints (pain, temperature, mobility, fluctuation, etc.). 
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PERCUSSION 
 topographic percussion of the chest (defining lung contours, mobility of the 
lower pulmonary edge, height of apexes standing, comparative percussion of the 
lungs); 
 determining absolute and relative borders of the heart; 
 defining boundaries and sizes of the liver and spleen; 
 defining the lower edge of the stomach; 
 defining free fluid in the peritoneal cavity; 
 presence of tenderness on percussion of the lumbar area. 
 
AUSCULTATION 
 determining physiological and pathological respiratory sounds; 
 heart sounds (volume, rhythm, rate, regularity, abnormal rhythms, presence 
of auscultatory phenomena); 
 determining of peristalsis presence. 
 
ADDITIONAL INFORMATION 
 аppetite; 
 sleep; 
 general neuropsychological state, mood; 
 menses, other vaginal discharge; 
 stool; 
 urination. 
 
Filling in case histories, it is necessary to describe in more details the system 
in which the disease is diagnosed/suspected, which caused hospitalization. Thus, 
for rheumatologic patient, the state of the musculoskeletal system is described in 
details, for hematologic – system of hemopoiesis, for endocrinologic – detailed 
description of those glands, that are accessible for physical inspection. 
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During the initial examination it is also necessary to carry out some 
instrumental and/or laboratory tests: 
 blood pressure measurement; 
 thermometry; 
 pulseoxymetry; 
 if needed: electrocardiography (ECG), complete blood count and urine tests, 
biochemical blood analyses (if necessary to clarify level of findings, which are 
specific already on the early stage of patient’s management), chest and/or 
abdomen X-ray, and ultrasound examination. 
In the protocol of the patient’s examination, all information obtained on 
physical examination is recorded. Based on the presence of pathology, the initial 
diagnosis is established. The initial diagnosis is established according to a leading 
syndrome and symptom complex of the patient. 
 
Stage III: formulation of the preliminary diagnosis 
 The diagnosis consists of two basic components: 
1. Clinical-anatomical diagnosis (pneumonia, hypertension, etc. The exception is 
only ischemic heart disease and its forms, in which there is no need to mention 
atherosclerosis). 
2. Clinical-functional part, which includes complications if there are any. 
Comorbidities are essential for the future patient’s management. If it is 
possible, at the stage of the initial examination of the patient it is necessary to show 
in fullest clinical-anatomical and clinical-functional diagnosis of concomitant 
diseases.  
 
Stage IV: drawing up examination and treatment plan 
Examination and treatment plan is drafted individually for every patient, 
considering peculiarities of the disease course, based on the approved local 
protocols of diagnosis and treatment. 
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The plan of examination includes laboratory, instrumental methods of 
examination and counseling by profile specialists. 
The treatment plan consists of defining patient’s regimen, diet, water intake 
regimen, drug treatment, physiotherapeutic procedures and exercise therapy. The 
plan approved during the initial examination is not final. It may be supplemented 
and changed according to the available data and current patient’s condition. 
 
Stage V: dynamic follow-up of the patient. 
Every day the patient is followed-up, information is recorded in the diary. 
The diary includes records on general dynamics of the patient’s condition, changes 
in the initial complaints, leading physical data and vital signs: blood pressure, heart 
rate, pulse rate, respiratory rate, data on pulseoxymetry, temperature and other 
ones, which are important to determine the state of the particular patient. 
Information about sleep, appetite, physical activity, frequency of urination and 
stool is recorded. At the end of the diary, it is necessary to specify and briefly 
justify supplements and changes in the treatment and/or examination of the patient. 
It is essential to indicate which doctor’s administrations were not carried out and 
for what reason, if such facts had been established.  
On the third day of patient’s hospital stay initial diagnosis should be 
reviewed and justified on the basis of the obtained additional investigations` 
results. Justification of the clinical diagnosis is based on: 
1. Clinical and paraclinical data, distinguishing leading symptom complex. 
2. The analysis of clinical presentation development and causes of the disease 
in dynamics (history of particular exacerbation, history of past 
exacerbations). 
Every 10 days of patient’s hospital stay, interim epicrisis is recorded in the 
case history. It includes the following information: dynamics of the main 
symptoms of the disease, data of additional methods of examination, administered 
treatment and its results, further tactics of the patient’s management.  
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MEDICATION ADMINISTRATION RECORD (MAR) 
The document is intended for coordinated work of doctors, nurses and 
paramedical personnel in the hospital. In MAR the regimen, diet, medications with 
exact dosage, frequency and route of administration, physiotherapeutic procedures 
are recorded orderly. The nursing staff registers the procedures, which have been 
carried out. The physician makes changes and supplements, monitors carrying out 
of his/her administrations. 
 
TEMPERATURE SHEET 
Obligatory temperature sheet should contain information on the dynamics of 
body temperature. It may also contain the following information: pulse, blood 
pressure, weight, respiratory rate, the amount of expectorated sputum, diuresis, and 
stool frequency. In patients with diabetes mellitus - level of blood and urine 
glucose, the dose of insulin should be recorded.  
 
EPICRISIS 
(Discharge summary) 
Epicrisis is written on patient’s discharge from the hospital according to the 
following example. 
The patient (last name and first name), age, stayed in the department from 
(date is indicated) till (date is indicated). He/she was hospitalized by the direction 
of (specify the establishment that referred the patient), taken urgently or according 
to schedule. The purpose of hospitalization (treatment, additional tests, was 
directed by the military enlistment office, etc.). In the hospital, the following 
diagnosis was established: the complete clinical diagnosis with a short 
substantiation. Data, which made it possible to justify diagnosis without describing 
in detail all the clinical data and conducted examination techniques should be 
indicated. Results of specialist’s consultations should be noted. All prescribed 
medications with indication of active substances and trade names, dosage and term 
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for use are listed (for antibiotics, hormones and cytostatics it is mandatory!). The 
total assessment of effectiveness of therapy: recovery, improvement (without 
changes or worsened) and prognosis of recovery and life is given. At the end of the 
summary, plan of the patient’s management after discharge from the hospital with 
detailed recommendations is provided. Expertise of a stable or temporary disability 
is performed (get back to work or discharged with the sick leave with indication of 
date visiting the doctor at the next stage, justification for referral for the working 
capacity examination). Epicrisis is necessarily certified by the signature and 
personal seal of the physician, head of the department and stamp of the hospital. 
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Еlectrocardiography (ECG) is a method of graphic registration of changes of 
cardiac potential differences, which arise during the process of myocardial 
excitation. 
ECG REGISTRATION TECHNIQUE 
Facilities for electrocardiography 
Electrocardiographs should be placed in a dry location at temperatures not 
below than 10°C and not higher than 30°C. During the work the ECG device must 
be earth grounded. 
ECG is performed in a special room at an appropriate distance from 
potential sources of electrical disturbances: electric motors, physiotherapeutic and 
X-ray rooms, switchboards. The couch must be placed at a distance not less than 
1,5–2 m from the cables. It is reasonable to shield the couch and put a blanket with 
the sewn wire cloth, which is earth grounded, under the patient.  
Investigation is conducted after 10–15 minutes’ rest and not earlier than 2 
hours after meal. The patient should be stripped to the waist. Legs also should be 
free from clothes. ECG recording is usually conducted in the patient’s supine 
position, this allows to achieve maximal muscle relaxation. 
Applying of electrodes  
In clinical practice 12 leads of ECG are used the most widely. Recording of 
them is mandatory in every ECG examination of the patient: 3 standard leads, 3 
enhanced unipolar leads from the limbs and 6 thoracic leads. 
On the inner surface of the legs and forearms in their lower thirds, 4 plate 
electrodes are placed by means of rubber belts. On the patient’s chest one or some 
(in multi-channel recording) thoracic electrodes are applied, using rubber suction 
cup. To improve ECG quality and to reduce the number of induced currents, it is 
necessary to ensure good contact of electrodes with the skin. Do this requires:  
1) previously to degrease the skin with alcohol in places of electrodes applying;  
RECOMMENDATIONS ON REGISTRATION AND ANALYSIS OF ECG 
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2) to moisten the skin with soapy solution in places of electrodes applying in case 
of hirsuties (excessive hair growth);  
3) to use the electrode paste or moisten the skin profusely with 5–10% solution of 
sodium chloride in places of electrodes applying.  
Attachment of wires to the electrodes. 
The wire which comes from the electrocardiograph and marked with a 
different color is attached to every electrode placed on the extremities or on the 
surface of the chest. Generally accepted marking of incoming wires is: right hand – 
red color; left hand – yellow; left leg – green, right leg (earth-grounding of the 
patient) – black; chest electrode – white (fig.1). 
Enhanced leads from the limbs register potential difference between one of 
the limbs on which an active positive electrode of this lead is applied (right arm, 
left arm or leg) and the average potential of the other two limbs. So aVR – 
enhanced lead from the right hand; aVL – enhanced lead from the left hand; aVF – 
enhanced lead from the left foot.  
To record the ECG, 6 generally accepted positions of active electrode on the 
front and lateral surface of the chest are used, they are connected with a combined 
Wilson’s electrode and form 6 chest leads: 
 lead V1 – in the fourth intercostal space along the right edge of the 
breastbone; 
 lead V2 – in the fourth intercostal space along the left edge of the 
breastbone; 
 lead V3 – between the positions of V2 and V4, approximately on the level of 
the fourth rib along the left parasternal line; 
 lead V4 – in the fifth intercostal space along the left medioclavicular line; 
 lead V5 – on the same level in horizontal plane as in V4, along the left  
anterior axillary line; 
 lead V6 – along the left medial axillary line on the same level in horizontal 
plane, as electrodes of V4 and V5 leads. 
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So, to the electrode V1 the wire with tag of red color is connected; to the 
electrode V2 – yellow, V3 – green, V4 – brown, V5 – black and V6 – blue or 
purple (fig. 2).  
Leads V7–V9. Active electrode is fixed along the posterior axillary (V7), 
scapular (V8) and paravertebral (V9) lines on the horizontal level, on which 
electrodes V4–V6 are placed. These leads are usually used for the more exact 
diagnostics of focal changes in the myocardium in the posterior-basal areas of the 
left ventricle.   
Leads V3R–V6R. Thoracic (active) electrode is fixed on the right side of the 
chest in positions symmetric with usual sites of electrodes applying. These leads 
are used to diagnose hypertrophy of right parts of the heart.  
 
Fig. 1. Scheme of applying standard and enhanced electrodes  
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Fig. 2. Scheme of thoracic electrodes fixing  
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Choice of electrocardiograph amplification 
Average amplification of each channel is selected in such a way that voltage 
of 1 mV causes deviation of galvanometer and recording systems equal to 10 mm. 
If needed, it is possible to change the amplification: to lower, in too large 
amplitude of ECG waves (1 mV = 5 mm), or to increase in small amplitude (1 mV 
= 15 or 20 mm).  
ECG recording. ECG recording is performed at quiet breathing and at the 
height of the inspiration (in lead III). In every lead not less than 4 cardiac cycles of 
PQRST is recorded. At the beginning of every curve, calibrated signal is shown. 
As a rule, ECG is recorded at a speed of paper movement of 50 mm/s. A lower rate 
(25 mm/s) is used if longer period of ECG recording is needed, for example – for 
arrhythmias diagnosing. To analyze the duration of the waves and ECG intervals,  
the following calculations may be done:  
In recording speed of 50 mm/sec 
 3000 mm in 60 seconds = 3000 small cells for 1 min = 600 large cells in 
1 min 
 1 small cell = 1 mm = 0,02 sec, 1 large cell = 5 mm = 0,1 sec 
 1 sec = 50 mm (5 cm) = 10 large/50 small cells 
 3 sec = 150 mm (15 cm) = 30 large/150 small cells. 
 
In recording speed of 25 mm/sec 
 1500mm in 60 seconds = 1500 small cells in 1 min = 300 large cells in 1 
minute 
 1 small cell = 1 mm = 0,04 sec, 5 mm = 0,2 sec 
 1 sec = 25 mm (2,5 cm) large = 5 large cells/25 small cells 
 3 sec = 75 mm (7,5 cm) = 15 large /75 small cells.  
 
Immediately after the investigation, on the paper tape the name and surname 
of the patient, date of birth, date and time of the investigation is written.  
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Waves, intervals and segments of ECG (fig. 3): 
 Р – depolarization of atria (right and left); 
 P-Q interval– the distance between the beginning of P wave and beginning 
of Q wave, time of impulse conducting through the atrio-ventricular node from the 
atria to the ventricles; 
 P-Q segment– the distance between the end of P wave and beginning of Q 
wave; 
 QRS – the distance between the beginning of  Q wave and the end of S 
wave, ventricular depolarization; 
 Q – the first negative wave of the complex after P; 
 R – positive wave; 
 R’ – the second positive wave; 
 S – negative wave after R; 
 Segment S-T (RS-T) – the distance between the end of QRS complex and 
beginning of T wave, the period of cardiac cycle when both ventricles are 
embrassed by excitation; point J ("joint") – end place of QRS complex and the 
beginning of ST segment (fig. 4); 
 T – repolarization of the ventricles; 
 Interval Q-T – the distance from the beginning of QRS complex to the end 
of T wave, the electrical systole of the ventricles (depolarization and 
repolarization) (fig. 5); 
 U – post-depolarization of the ventricles; 
Small letters (q, r, s) are used for waves of the small amplitude (less than 5 mm).  
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Fig. 3. Waves, intervals and segments of ECG 
 
 
 
 
 
 
 
 
 
 
Fig. 4. Defining of ST segment and “j” point on the ECG 
 
 
Fig. 5. Defining of Q-T interval 
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Version of normal ECG (25 mm/s) is shown on fig. 6. 
 
Fig. 6. Normal 12-leads ECG 
GENERAL PLAN OF ECG DECODING  
I) Analysis of the heart rhythm and conductivity: 
1) defining of excitement source; 
2) assessing of regularity of heart rate; 
3) calculation of HBR; 
4) evaluation of conductivity function. 
II) Defining of position and rotation of electrical heart axis in the frontal plane; 
III) Analysis of atrial P wave. 
IV) Analysis of ventricular complex QRST: 
1) analysis of QRS complex; 
2) analysis of S-T segment; 
3) analysis of T wave; 
4) analysis of Q-T interval. 
V) Electrocardiographic conclusion. 
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For more detailed ECG analysis, algorithm of record decoding, regarding the 
most common changes is given.  
 
 
Fig. 7. Elevation of ST segment due to early ventricular repolarisation 
syndrome 
 
 
Fig. 8. Changes of T wave on ECG. Voltage is saved QRS > 5 mm standard 
leads, QRS > 8mm thoracic leads  
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Examples of conclusion formulation. 
Example 1. Conclusion: Sinus rhythm, regular. Heart rate is 68 bpm. Normal 
heart axis. Voltage is sufficient. 
Example 2. Conclusion: Non-sinus rhythm, irregular. Atrial fibrillation with 
the ventricular rate of 110/min. Horizontal heart axis. Signs of LVH. Voltage is 
sufficient.  
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ALGORITHM OF THE ECG DECODING  
Evaluation of the 
regularity of the 
rhythm 
Determination of 
the pacemaker 
Р wave: 
1. Р"+" ІІ, Р"-" aVR 
stable form 
2. Stable PQ 0,11-
0,2 s 
3. Р-Р = R-R 
Sinus rhythm 
Not sinus 
rhythm 
 Wave Р 
changed (Р') or 
absent  
Difference Р-Р/R-R < 10% 
Difference Р-Р/R-R > 10% 
Wave Р': 
1. Deformed / two-phase / 
negative  
2. QRS – not changed 
3. R-R the same 
Regular 
Sinus arhythmia 
Atrial 
AV-nodal 
AV-nodal 
Idioventricular 
Wave Р': 
1. Р"-" ІІ, ІІІ, aVF  
2. QRS not changed 
3. R-P` 0,1-0,2 s 
4. P` after QRS 
Wave Р' absent: 
1. QRS, T - not changed  
2. R-R is the same 
3. Heart rate - 30-60/minute 
Wave Р: 
1. Р"+" ІІ, Р"-" aVR stable form or 
absent  
2. R-R > P-P 
3. QRS > 0,12 s 
Irregular 
The duration of R-R 
differs> 10% 
(arrhythmia); 
evaluate the 
ventricular rate 
Regular 
R-R duration is equal 
Yes 
No 
Extrasystole / 
Parasystole 
Supraventricular 
arrhythmias 
(QRS < 0,12 s) 
AV-nodal 
tachycardias 
(QRS <0,12 s) 
Ventricular 
tachycardias 
(QRS > 0,12 s) 
P - is absent; wave f (F) with 350-500 / 
min (250-350 / min), in II, III, aVF, V1-V2; 
No baseline; different amplitude of QRS 
Atrial fibrillation/ 
atrial flutter 
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ALGORITHM OF THE ECG DECODING  
 (продовження) 
«P» wave evaluation 
Determination of 
heart rate 
Duration of R-R is 
equal  
Sinus (not 
changed) 
Atrial 
hypertrophy 
60 (𝑠) 
𝑅 − 𝑅 (𝑠)
 
The ruler/The table 
V-50 mm/s 
600
𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑏𝑖𝑔 𝑐𝑒𝑙𝑙𝑠
 
 
V-25 mm/s 
300
𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑏𝑖𝑔 𝑐𝑒𝑙𝑙𝑠
 
< 60/minute 
bradycardia 
60-90/minute 
normocardia 
> 90/min 
tachycardia 
Left atrium 
(P-mitrale) 
Right atrium 
(Р-pulmonale) 
Amount of complexes 
QRS in 3 s * 20 
Amplitude ≥ 0,25 mV 
Duration ≥ 0,1-0,12 s 
PIII > PII > PI 
tall, peaked 
Amplitude ≥ 0,25 mV 
Duration ≥ 0,1-0,12 s 
PI > PII > PIІІ 
Two-humped/plateau on the top 
Amplitude < 0,25mV 
Duration < 0,1 s 
PII > PI > PIII 
Irregular 
Regular Yes 
No 
No 
Yes 
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ALGORITHM OF ECG DECODING  
 (продовження) 
Interval PQ 
Determination of 
the heart axis 
RII>RI>RIII 
Not changed 
Violation of AV 
conduction 
RaVF=SaVF 
RII>SII, RaVF<SaVF 
Horizontal  
Mild deviation to the 
left  
Syndrome of early excitation 
(WPW, CLC) 
AV- blockade І stage. 
PQ<0,11 
PQ>0,2 
0,11<PQ<0,2 
stabled 
Vertical  
Not deviated 
No 
Yes 
RIII=RII>RI 
RI=SI 
RIII>RII>RI 
RI>RII>RIII 
SIII>RIII 
RII≤SII Severe deviation to 
the left  
SaVR≤RaVR 
SaVR>RaVR Mild deviation to the 
right 
Severe deviation to 
the right 
Lengthening PQ with each beat to 
the loss of QRS 
Irregular loss of QRS without 
prolongation PQ 
AV-blockade ІІ st. І type 
AV-blockade ІІ st. ІІ type 
The absence of communication 
between P and QRS (AV-
dissociation) 
AV-blockade ІІІ st. 
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ALGORITHM OF THE ECG DECODING  
 (продовження) 
Duration of 
the complex  
Not changed 
To evaluate 
waves R and Q 
QRS ≥0,12 s 
Wide monomorph R without q in I and 
V6 
Wide monomorph S with  possible r in 
V1 
QRS≥0,12 s 
rsr ', rsR', rSR 'in V1 and/or V2 
S longer than the R or ˃0,04 s in I 
and V6 
Blocked left bundle of 
His 
Blocked right bundle 
of His 
 
Hyprthrophy of left 
ventricle 
R V5/V6 + S V1 >35 mm 
R aVL + S V3 >28 mm ♂ 
R aVL + S V3 >20 mm ♀ 
 
Amplitude S <20 mm 
(The largest in aVR); 
Regression S from V1 to 
V4; R = S in V3 
(transitional zone) 
Delayed 
conduction 
Not changed 
QRS˂0,11 s 
No 
Yes 
QRS˃0,12 s 
Heart rate - 30-45/min or 
the presence of "spikes» 
Electrolyte 
disturbances (Hyper 
K +/Ca2+) 
R/S V1 >1, or R/S уV5 or V6 ≤1 
R V1 ≥7 mm; R V1+S V5/V6 >10.5 mm 
rSR= in V1 with R'= > 10 mm 
QRS˃0,11 s 
Idioventricular/impo
sed rhythm 
QIII – SI 
(the sign Mak Jin-White) 
The sharp right 
ventricular overload 
(pulmonary embolism) 
SI˃SII˃SIII 
Electrical axis type SI-
SII-SIII 
 Q
R
S 
co
m
p
le
x 
 Q wave 
 R wave 
S wave 
In all leads except aVR: 
Duration Q <0,03 s; 
Amplitude Q <1 / 4R 
No 
 
Yes  
Pathologic 
scar changes 
In all standard leads except 
aVR; 
Growth from V1 to V4 and 
reduction from V5 to V6; 
It may be absent in 
V1-V2 in patients <30 years 
No 
 
Yes  
 Not changed 
Changed; 
to evaluate the 
electrical axis 
of the heart Hyprthrophy of right 
ventricle 
 
Not changed 
Yes  
 
No 
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ALGORITHM OF THE ECG DECODING  
 (продовження) 
ST segment 
in two or more contiguous 
leads: ≥ 0,05 mV 
≥0,1 mV in ≥2 contiguous 
leads + symptoms of 
ischemia; V2-V3: 
♂ ≥0,20 mV aged> 40 years 
     ≥0,25 mV aged ˂40 years 
♀ ≥0,15 mV 
In all leads except aVR 
ACS with ST-segment 
elevation 
(Transmural lesions) 
Early repolarization 
syndrome 
Only in leads V1 and aVR 
Elevation of ST 
Not changed 
In standard leads on 
isoline (± 0,5 mm); 
V1-V3 ≤2,0 mm 
V4-V6 ≤0,5 mm 
No 
 
Yes  
 
ACS whithout 
elevation of segment 
ST(Subendocsrdial 
lesions) 
without elevation 
concave ST elevation and clear J wave 
expressive decrease of R and/or 
expressive point J 
more expressive in the chest leads 
the absence of reciprocal ST 
depressionвеликі симетричні Т 
In the absence of the aforementioned states to consider the 
following reasons: hypotermy, stroke, hyperkalemia, 
hypertrophic cardiomyopathy, Brugada syndrome, aneurysm and 
slaughtering of the heart. 
In the absence of symptoms of ischemia to consider the following reasons: LVH, 
left ventricular overload, overdose of digoxin, hypokalaemia/hypomagnesaemia 
changes after an episode of tachycardia, reciprocal changes 
Depdddression 
of ST 
Acute pericarditis 
PE 
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ALGORITHM OF ECG DECODING  
 (продовження) 
T wave 
Sharp-pointed and inverted (T> 
0.5mm 
«-» T in I,kk II, V3, V4, V5, V6), 
in ≥ 2 contiguojjjjjus leads + 
symptoms of ischemia; 
transmural / 
subepicsrdial 
ischemia under the 
electrode 
Subendocardial 
ischemia on the 
opposite wall 
QTs ˂ 0,34 s 
Changed 
Not changed 
Т"+" I, II, aVF, V2-V6 
TI>TIII, TV6>TV1 
T"-" aVR 
 Amp. <0,50-0,60 mV 
Dur. 0,16-0,24 sec 
No 
 
Yes  
 
♂ QTs ˃ 0,45 s 
Non-specific changes 
or peripherals zone of 
ischemia 
Flattened T 
(T <0,5 mm «- / +» T 
in I, II, V3, V4, V5, V6) 
Syndrome of prolonged QT 
(congenital), an overdose of 
Reduced QT syndrome 
Two-phase, split, two-humped, 
wide 
Changed 
High and acuminate 
Subendocardial 
ischemia under the 
electrode or 
transmural on the 
opposite wall 
Interval Q-T 
𝑄𝑇𝑠 =
𝑄𝑇 (𝑠)
√𝑅 − 𝑅 (𝑠)
 
 
♂ QTs ˂ 0,45 s 
♀ QTs ˂ 0,46 s 
Not changed Yes  
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Notes. ACS – acute coronary syndrome; LVH – left ventricular hyperthrophy; 
LBBB – left bundle branch block; RBBB – right bundle branch block; PE – 
pulmonary embolism; LAH – left anterior hemiblock; LPH – left posterior 
hemiblock. 
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Blood pressure measurement on the upper extremities
 
The 
position of 
the patient
• Lying and standing, sitting in a comfortable position. The shoulder is located at the 
heart level.
Conditions
• Тhe state of rest at least 5 minutes, do not smoke or drink coffee during 30 minutes 
before the examination. If the examination was preceded by a significant physical 
loading, the rest period should be prolonged to 15 minutes.
Equipment
• Мercury tonometer is recommended. Other devices require regular calibration. 
Standard cuff size (12-13 cm wide and 35 cm long) should cover at least 80% of 
the arm circumference and 2/3 of its length. Using too narrow and short cuff leads 
to higher blood pressure indicators, too wide - to their underestimation. In patients 
with muscular and thick arms the cuff length of 42 cm should be used; in children 
under 5 years - 12cm.
Frequency 
rate of 
measureme
nt
• To perform at least twice with intervals of 1 minute. The measurement is carried out 
repeatedly after a few minutes when the difference of results is more than 5 mm Hg. 
The final result is considered to be the average value of the last two measurements.
Measureme
nt 
technology
• The cuff is placed in the middle of the shoulder and at the level of the heart.  Its 
lower edge is 2-2,5 cm above the cubital fossa. Between the cuff and the shoulder 
surface a finger must pass. On the first measurement of blood pressure it is 
recommended firstly to determine SBP by palpatory method. For this, it is 
necessary to determine the pulse on the a.radialis and then quickly pump up the 
cuff to 70 mm Hg. Further it is necessary to pump by 10 mmHg to the value, 
when the pulsation on a.radialis disappears. Then start to release air from the cuff. 
The rate at which pulsation on a.radialis appears during air discharging 
corresponds to the SBP. Such palpation method of determining blood pressure 
helps to avoid errors associated with "auscultatory flop" - the disappearance of 
Korotkoff sounds immediately after their first appearance. Measurement of blood 
pressure by auscultatory method: the air is pumped by 20-30 mmHg above the 
SBP values which were determined by palpation. The air is deflated slowly - 2 
mm per second and the phase I of Korotkoff sounds (appearance) and phase V 
(disappearance) is determined, which correspond to the SBP and DBP. On 
auscultation of Korotkoff tones at very low values or up to 0, DSB level is 
considered to be the level of BP, which is fixed at the onset of phase V.
• NB! Blood pressure is measured with an accuracy of 2 mmHg.
Specific 
recommend
ations
• Measurement of blood pressure on the first and fifth minutes after transition in 
orthostasis is mandatory in elderly patients, patients with diabetes mellitus and in 
all cases of orthostatic hypotension or when it is suspected.
ALGORITHM OF BLOOD PRESSURE (BP) MEASUREMENT  
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Blood pressure measurement on the lower extremities 
(peculiarities and differences) 
The position of 
the patient
• Procumbent position (lying 
face down).
Conditions
• The state of rest during 5 minutes; it is conducted after BP measurement 
on the upper extremities.
Equipment
• Large size of the cuff (42 cm in length)
Frequency rate 
of measurement • Тwice, with an interval of 1 minute
Measurement 
technology
• The cuff is placed 2-3 cm above the popliteal fossa 
according to the rules of investigation on the upper 
extremities. The membrane of the phonendoscope is placed 
in the popliteal fossa.
Specific 
recommendat
ions
• BP measurement on the ankles to determine malleolar-brachial index of 
systolic blood pressure is carried out by doplerometry or pulsometry.
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The risk of cardiovascular diseases (CVD) is the probability of 
cardiovascular events development in a person due to atherosclerosis within a 
specified period of time. 
At the current stage it is proposed to use the pattern of total risk determining 
based on the SCORE system (Systematic Coronary Risk Evaluation – systematic 
evaluation of coronary risk). The system estimates a 10-years’ risk of development 
of the first fatal event due to arteriosclerosis (myocardial infarction, stroke, aortic 
aneurysm, etc.). In the SCORE system the following risk factors are used: gender, 
age, smoking, SBP, total cholesterol or cholesterol and HDL ratio.  
The total cardiovascular risk can be easily calculated using the diagram 
(fig. 9). 
METHODICAL RECOMMENDATIONS ON EVALUATION OF TOTAL 
RISK OF CARDIOVASCULAR DISEASES  
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Fig. 9. 10-years’ risk of fatal CVD in high-risk regions of Europe, taking 
into account gender, age, systolic blood pressure (SBP), total cholesterol and 
smoking. 
 
Instructions for using the diagram. To assess personal 10-years’ risk of 
cardiovascular death it is necessary to find an appropriate place in the table 
considering sex, age, smoking status. Find a place in the table with the closest 
value of SBP (mmHg) and total cholesterol (mmol/L or mg/dL).
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An adult person that has: 
• desire to assess the overall risk, or 
• one or more risk factors such as smoking, excessive body mass and hyperlipidemia, or 
• positive family history of premature cardiovascular disease development or major risk factors (hyperlipidemia), or 
• symptoms that indicate the presence of CVD 
Asking about complaints and anamnesis taking, measurement of blood pressure, smoking status precising, determination of total cholesterol level, low 
density lipoprotein (LDL), high density lipoproteins (HDL) and triglycerides (TG) in serum 
Evaluation of total cardiovascular risk by the SCORE scale (Fig. 9) 
Low risk 
˂ 1% 
Recommendations 
on lifestyle 
modifications, 
dynamic 
monitoring 
Moderate risk 
≥ 1% and ˂ 5% 
Recommendations 
on lifestyle 
modifications, re-
evaluation by the   
SCORE scale and 
determination of 
serum lipids after 3 
months 
LDL ˂3,0 mmol/L 
High risk 
≥ 5% and ˂ 10% or 
Significantly elevated single risk factor, such as 
familial dyslipidemia and severe hypertension. 
Patients with diabetes mellitus type 1 and 2 without 
risk factors or damage of target organs. 
Patients with moderately severe chronic kidney 
disease (GFR 30-59 ml/min/1,73m2) 
Recommendations on lifestyle modifications, 
drug therapy to achieve target levels of LDL 
LDL ˂2,5 mmol/l 
Very high risk 
≥ 10% or 
The established diagnosis of CVD, MI in 
anamnesis, ACS, revascularization of the coronary 
arteries was performed, ischemic stroke, peripheral 
artery atherosclerosis. 
Patients with diabetes mellitus type 2 and type 1 
with damage of target organs (microalbuminuria, 
etc.). 
Patients with severe chronic kidney disease (GFR 
˂30 ml/min/1,73m2) 
Recommendations on lifestyle modifications, 
drug therapy to achieve target levels of LDL 
LDL ˂1,8 mmol/L, and / or reduction of ≥50% 
if it is impossible to achieve the target level 
ALGORITHM OF EVALUATION OF TOTAL RISK OF CARDIOVASCULAR DISEASES ESTIMATION 
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Body mass index (body mass index (BMI) – value which allows to evaluate the 
degree of conformity of body mass and height of a human, and thereby to evaluate 
if body mass is deficient, normal or excessive. This index is important for 
determining indications of necessity of treatment.  
Defining body mass index by Kettler was done by the formula:  
BМI (kg/m2) = body mass (kg)/height2 (m) 
Normal BMI is considered to be within the limits of 18,5–24,9 kg/m2, deficit –
 < 18,5 kg/m2, excessive body mass – 25–29,9 kg/m2, obesity І degree – 30–34,9 
kg/m2, obesity ІІ degree – 35–39,9 kg/m2, obesity ІІІ degree – > 40 kg/m2 [166]. 
BMT is necessary to evaluate in patients with cardiovascular diseases, diseases of 
endocrine glands, as well as in patients with community-acquired pneumonia. In 
community-acquired pneumonia both overweight/obesity and deficit body mass is 
an unfavorable factor of the disease course.  
 
  
 
 
The study of external respiration function (ERF) is performed by spirometry 
with graphic representation of "flow-volume" loop. Spirometry is a method of 
determining ERF by measuring the amount of air that the patient can expire from 
the lungs with maximal effort after maximal deep inspiration. 
 Indications for spirometry are: 
1. Determining presence and type of ventilation disorders. 
2. Determining reversibility of violations in the existing bronchial obstruction. 
3. Determining the impact of therapy 
4. Monitoring of ventilation disorders in dynamics. 
 
There are no absolute contraindications for spirometry! 
DEFINING AND EVALUATION OF BODY MASS INDEX 
 
 
GUIDELINES ON INTERPRETATION OF EXTERNAL 
RESPIRATION STUDY 
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Relative contraindications for spirometry are: 
1. Acute coronary syndrome at the time of the study or suffered less than 6 
months ago. 
2. Violation of the heart rate. 
3. Mental disorders. 
4. Severe cardiac and respiratory failure (presence of dyspnea at rest). 
5. Hyperthermia. 
6. Expiratory apnea. 
7. Pulmonary tuberculosis. 
8. Pneumothorax 
Rules of patient’s preparation for spirometry 
1. Spirometry is performed in clinically stable condition of a patient without 
concomitant infection of the respiratory tract. 
2. Short-acting bronchodilators are not used for at least 4 hours, prolonged – 12 
hours, methylxanthines of prolonged action – 24 hours prior to the study. 
3. The patient should avoid smoking for at least 1 hour prior to the study. 
4. The study should not be conducted strictly on an empty stomach, but 
patients should refrain from eating large quantities of food and/or beverages. 
Key parameters of spirometry: 
Vital capacity (VC) – the amount of air at the maximal inspiration and expiration 
(measured in liters). 
Forced vital capacity (FVC) – vital capacity, which is determined during a forced 
breathing maneuver (measured in liters).  
FEV1 – forced expiratory volume in the first second with the maximal expiratory 
flow. 
FEV1/FVC – FEV1 and FVC ratio, which is designated as a fraction (previously 
was designated in percentages). 
Regulatory parameters are determined for every patient individually, taking 
into account gender, height, age and race. 
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Evaluation of the spirometry data is done by relative parameters that reflect 
the ratio of patient’s absolute values, obtained in the course of investigation to 
appropriate (predicted). 
RF values 
Parameters,  Norm Ventilation violations 
moderate significant severe 
VC, % from 
predicted 
≥ 80 79-60 59-51 <50 
FEV1, % from 
predicted 
≥ 80 79-60 59-41 <40 
FEV1/FVC 0,7-0,8 
not taken into account in determining severity of 
ventilation violations * 
Note: *- important in determining type of ventilation disorders. 
 
Examples of conclusions of ERF study: 
1. Respiratory function is normal: all parameters are normal 
2. Ventilation disorders (moderate, significant or severe) according to obstructive 
type: in conditions of FEV1 decrease and/or FEV1/FVC less than 0.7). 
3. Ventilation disorders (moderate, significant or severe) according to restrictive type:  
in conditions of VC or FVC decrease (if VC parameter is not available). 
4. Ventilation disorders (moderate, significant or severe) according to mixed type. 
The degree of severity depends on the parameter (VC or FEV1), which is 
decreased to a large extent. 
5. Ventilation disorders (moderate, significant or severe) according to mixed type 
with predominance of obstruction: in conditions when FEV1/FVC is less than 0,7.  
6. Ventilation disorders (moderate, significant or severe) according to mixed type  
with predominance of restriction: in conditions when FEV1/FVC is more than 0,9. 
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ALGORITHM OF SPIROGRAM ANALYSIS  
Assessment of maneuver correctness 
 
Assessment of FEV1 
Norm FEV1 ↓ 
Assessment of 
FEV1 / FVC 
Assessment of 
FEV1 / FVC 
 
Norm 
Assessment of FVC 
Norm FVC ↓ 
ERF is normal Restrictive type of 
ventilation disorders 
Norm FEV1 / FVC ↓ 
Assessment of FVC 
 
Assessment of FVC 
 
Norm Norm FVC ↓ FVC ↓ 
Obstructive type of 
ventilation disorders 
 
Mixed type of ventilation 
disorders with predominance 
of obstruction 
 
Mixed type of ventilation 
disorders with predominance 
of restriction 
 
ERF is normal 
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Examples of study protocols 
Example 1 
Parameter Predicted, l Actual, l Relative index, % 
FVC 5,81 6,87 118,3 
FEV1 4,65 5,70 122,4 
FEV1/ FVC  82,8 (0,8)  
Conclusion: ERF is normal 
 
Example 2 
Parameter Predicted, l Actual, l Relative index, % 
FVC 2,84 1,73  60,8 
FEV1 2,42 1,56  64,4 
FEV1/ FVC  90,4 (0,9)  
Conclusion: moderate ventilation disorders by mixed type. 
 
Example 3 
Parameter Predicted, l Actual, l Relative index, % 
FVC 3,76 3,30  87,7 
FEV1 2,79 1,03  36,8 
FEV1/ FVC  31,2 (0,3)  
Conclusion: severe obstructive ventilation disorders by obstructive type. 
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Example 4 
Parameter Predicted, l Actual, l The relative index, 
% 
FVC 3,76 2,80  74,46 
FEV1 2,79 1,03  36,8 
FEV1/ FVC  31,2 (0,3)  
Conclusion: severe ventilation disorders by mixed type with predominance of 
obstruction. 
Bronchodilator reversibility test 
In case of obstructive ventilation insufficiency by obstructive type, 
bronchodilator reversibility test is conducted using bronchodilator drugs (e.g. 
salbutamol 400 mcg). 
Bronchodilator reversibility test is performed in 15 minutes after drug using. 
Evaluation of the results: increase of FEV1 more than by 200 ml or 12% as 
compared to its basic value points to reversibility of bronchial obstruction (positive 
test), if it is less than 200 ml or 12% - negative one. 
Percentage of rise of FEV1 parameter is calculated by the formula:  
            EV1(after test) – FEV1(before test)/ FEV1(before test) x 100%  
 
Examples of study protocols (continuation) 
Example 5 
Parameter Predicted, l Actual pre 
test, l 
Relative 
index, % 
Actual post 
test, l 
FVC 3,03 2,44  80,4 2,67  
FEV1 2,62 1,62  61,7 1,66  
FEV1/ FVC  66,3 (0,6)  61,95 (0,6) 
((FEV1 post) – FEV1 pre)/ FEV1 pre))×100 % = ((2,67–2,44)/2,44)×100 %=9,42%. 
FEV1 reversibility less than 200 ml. 
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Conclusion: moderate obstructive ventilation disorders. Test on reversibility of 
airflow obstruction is negative. 
 
Example 6 
Parameter Predicted, l Actual pre 
test, l 
Relative 
index, % 
Actual post 
test, l 
FVC 2,38 2,39  100,3 2,76  
FEV1 2,40 1,01  50,6 1,23  
FEV1/ FVC  42,26 (0,4)  44,46 (0,4) 
 ((FEV1 post) – FEV1 pre)/ FEV1 pre))×100 % = (1,23–
1,01)/1,01×100 %=21,78 %. FEV1 reversibility more than 200 ml. 
Conclusion: moderate obstructive ventilation disorders. Test on reversibility of 
airflow obstruction is positive. 
. 
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Peak flowmetry is a method of functional diagnostics to determine the 
volumetric rate of peak expiratory forced rate (PEFR). PEFR is the main index 
which correlates with bronchial obstruction – forced expiratory volume in the first 
second (FEV1), so it can be recommended as its analogue for the use in the 
outpatient conditions and for individual use by the patient primarily. 
Aim of the study are: 
• revealing of bronchial obstruction as a screening 
method (used only when spirometry is inaccessible!); 
• monitoring of bronchial obstruction with 
possible prediction of exacerbations; 
• monitoring of treatment effectiveness in patients 
with bronchial-obstructive pathology. 
 
An indicator, calculated for the population considering sex, age and height of 
the patient can be considered as the conventional norm. An indicator, which is 
calculated for the general population does not always correspond to normal one for 
a particular patient. In this case it is optimally to consider average PEFR, measured 
in remission period when the patient is in the best state of health as the normal one.  
As a standard, it is necessary to accept measuring amplitude of fluctuations of 
PEFR (difference between morning value before bronchodilator usage, if a patient 
uses it, and evening value), which is expressed as percentage and calculated by the 
formula: 
Daily fluctuation = evening PEFR – morning PEFR ×100 
    ½(evening PEFR – morning PEFR) 
Value of amplitude of fluctuations in daily measuring of PEFR is a reliable 
index of stability and/or disease severity. Value of amplitude of fluctuations more 
than 20% is considered to be significant: 
PEFR less than 20% - stable state  
Algorithm of performance and analysis of peak 
flowmetry results 
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PEFR more than 20% - exacerbation, increase of hyperactivity 
 For patients with bronchial asthma the system of signal zones under the 
principle of traffic lights is used: 
 Green Zone - the best value of the patient is multiplied by 0,8. PEFR value 
more than the obtained result is within the green zone – zone of a stable state, 
when value of amplitude of daily fluctuations is less than 20%. 
Yellow Zone – values between the green zone and the value, obtained in 
multiplying the best patient’s PEFR value by 0,6. This zone corresponds to non-
severe exacerbation, when amplitude of daily fluctuations makes up 20-30%.  
Red Zone – patient’s PEFR value is below the yellow zone, daily fluctuations 
exceed 30%, this means exacerbation.  
В методичке этой таблицы нет. Проверить не могу.Table 1 
Peak flow readings according to the American Lung Association 
Zone Reading Description 
Green Zone 80 to 100 percent of the 
usual or normal peak flow 
readings are clear. 
A peak flow reading in 
the green zone indicates 
that the asthma is under 
good control. 
Yellow Zone 50 to 79 percent of the 
usual or normal peak flow 
readings 
Indicates caution. It may 
mean that respiratory 
airways are narrowing 
and additional medication 
may be required. 
Red Zone Less than 50 percent of 
the usual or normal peak 
flow readings 
Indicates a medical 
emergency. Severe airway 
narrowing may be 
occurring and immediate 
action needs to be taken. 
This would usually   
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involve contacting a 
doctor or hospital. 
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Table 2 
MARGINAL PEFR VALUES IN MEN 
Patient's position
•study  may be conducted both in standing and sitting position of a patient, but the position 
chosen should be constant during peak flowmetry performance;
Circumstance
• in the morning after sleep, or when the patient wakes up because of asthma attack, in the 
evening before going to bed;
Equipment
•mechanical peak flowmeter (a plastic tube or box with a graduated scale) or electronic one; 
when using mechanic one, diagram should be drawn, based on two-dimensional scale, 
where the X axis represents time of the day and the day, and the axis Y - PEFR values in 
L/min. Electronic peak flowmeter stores data in its own memory devices and needs 
transferring them to a computer for further analysis;
Multiplicity of 
measurement
•PEFR is studied  twice a day, in the morning and in the evening, the maneuver is repeated 
three times with small intervals, maximal value is recorded and written down in the 
diagram;
Measuring 
technique
•peak flowmeter must be placed strictly horizontally, it is neded to avoid contact with a
graduated scale to prevent mechanical dislocation of indicating hand (when using a
mechanical peakflow meter);
• in the beginning of measurement the indicating hand is set to zero (in electronic device -
display is set to "zero"), a patient performs a maximal quiet breath, then tightly clasps 
mouthpiece  with lips and performs a forced exhalation;
Specific 
recommendations
•standards for healthy persons of different age groups, patients of different height and 
gender are evaluated according to calculation tables (see below), but the maximal value for 
patients is measured in remission period and/or control  of the disease.
Algorithm of performance and analysis of peak flowmetry 
results 
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AGE (YEARS) 
HEIGHT 
(SM) 
5 8 11 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 
100 39 39 39  
 
 
 
 
105 65 65 65 
110 92 92 92 
115 118 118 118 
120 145 145 145 
125 171 171 171 
130 197 197 197 
135 224 224 224 
140 250 250 250 414 456 481 494 499 497 491 480 467 452 436 418 400 381 362 
145 276 276 276 423 466 491 504 509 508 501 491 477 462 445 427 408 389 370 
150 303 303 303 432 475 501 514 519 518 511 500 487 471 454 436 417 397 378 
155 329 329 329 440 484 510 524 529 527 520 510 496 480 463 444 425 405 385 
160 356 356 356 448 492 519 533 538 536 530 519 505 489 471 452 432 412 392 
165 382 382 382 456 500 527 542 547 545 538 527 513 497 479 460 440 419 399 
170 408 408 408 463 508 535 550 555 554 546 535 521 504 486 467 447 426 405 
175 435 435 435 469 515 543 558 563 561 554 543 528 512 493 474 453 432 411 
180 PEFR in 
children 
before 11 
years of age  
depends on 
height only 
476 522 551 566 571 569 562 550 536 519 500 480 459 438 417 
185 482 529 558 573 578 576 569 557 543 525 506 486 465 444 422 
190 488 536 564 580 585 583 576 564 549 532 513 492 471 450 428 
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Table 3  
MARGINAL PEFR VALUES IN WOMEN 
 
 
  
 AGE (YEARS) 
HEIGHT 
(SM) 
5 8 11 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 
100 24 24 24  
 
 
 
 
105 51 51 51 
110 77 77 77 
115 104 104 104 
120 130 130 130 
125 156 156 156 
130 183 183 183 
135 209 209 209 
140 236 236 236 348 369 380 384 383 379 371 362 352 340 328 316 302 289 276 
145 262 262 262 355 376 387 391 390 385 378 369 358 347 334 321 308 294 281 
150 289 289 289 360 382 393 397 396 391 384 375 364 352 340 327 313 300 286 
155 315 315 315 366 388 399 403 402 397 390 381 370 358 345 332 318 304 290 
160 342 342 342 371 393 405 409 408 403 396 386 375 363 350 337 323 309 295 
165 368 368 368 376 398 410 414 413 408 401 391 380 368 355 341 327 313 299 
170 394 394 394 381 403 415 419 418 413 406 396 385 372 359 346 331 317 303 
175 421 421 421 385 408 420 424 423 418 411 401 389 377 364 350 335 321 307 
180 PEFR in 
children 
before 11 
years of age 
depends on 
height only 
390 413 390 413 425 429 428 423 415 405 394 381 368 354 339 
185 394 417 394 417 429 433 432 427 419 409 398 385 372 358 343 
190 398 421 398 421 433 438 436 432 424 414 402 389 375 361 347 
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Image 
projection
• frontal or back frontal, right or left lateral, frontal or back oblique: the first or the 
second.
Special 
conditions
• in sitting or lying position due to severity of patient's state; with respiratory dynamic blurrness of 
image due to patient's unconsciousness, etc.
Image 
quality
•physical and technical characteristics: optical density, contrast, acutance; lack of artifacts and veil
Soft 
tissues of 
the chest
•volume, structure, presence of foreign bodies or free gas after injuries, etc.
Chest 
skeleton 
and 
shoulder 
girdle
•position, shape, size and structure of bones, ribs, sternum, visible cervical and thoracic vertebrae,
clavicles, shoulder blades, heads of shoulder bones; state of ossification center and areas of growth
in children and young people
Lung 
fields
•area, shape, transparency;
• in detecting symptoms of pathology (extensive or limited shadowing or radio-lucency of the focus -
round or  ring-like shadow) - detailed description of their position, shape, sizes, shadow density, 
structure, contours;
• lung pattern, distribution of elements, architectonics, caliber, character of contours.
Lung 
roots
•position, shape, size, structure, contours of elements, presence of additional structures.
Mediastin
um
•position, shape and width as a whole and characteristics of separate organs.
Conclusion
•X-ray (clinical and radiological) conclusion;
• recommendations.
GUIDELINES ON CHEST X-RAY INTERPRETATION 
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ALGORITHM OF CHEST RADIOGRAPHS ANALYSIS 
 
Mediastinum organs 
Not shifted Shifted 
Pulmonary or extrapulmonary lesion Towards shadowing 
Shadowing of the entire half of the 
chest  
Intensity of shadowing 
Significant Low or average 
Destruction of lung tissue Infiltration without destruction 
Diaphragmatic 
hernia 
Shadow structure 
dow 
Homogeneous Heterogeneous 
Pleural 
effusion 
Atelectasis, fibrothorax 
after lobectomy 
Pneumofibrosis, 
cirrhosis of the lung 
Shadowing of less than half of 
the chest  
Pleural effusion 
Fibrinous 
pleurisy 
Homogeneous shadowing Radio-lucency on the 
background of shadows  
In the opposite direction 
затемненню 
Lesion of lung tissue Pathology of pleural cavity 
Shadow structure 
Heterogeneous Homogeneous 
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According to modern principles of management of adult patients with CAP, 
a great number of them should be safely treated in out-patient units.  Outpatients 
with CAP treated with oral antibiotics return to work or usual activity level on 
average 6-9 days earlier than those admitted to the hospital with equivalent 
severity-of-illness.  Hospital admission increases CAP treatment costs nearly by 20 
times, as compared to outpatient therapy. 
Recently, two separate risk stratification instruments, CURB-65 and 
Pneumonia Severity Index (PSI) have been developed. 
CURB-65 is a simple scoring system easily used in the outpatient office or 
emergency room, it assigns 1 point for each of 5 clinical finding (table 4).  
In 2006 Australian-American team of experts proposed scale SMART-COP  
(table 8) to determine patients’ requirements in respiratory support and 
vasopressors. Also it is possible to use its variant, SMRT-CO (without specifying 
levels of albumin and pH of arterial blood).  
 
 
Table 4 
СURB-65/СRB-65 
Clinical Finding Points 
C – Confusion 1 
U – Blood urea nitrogen ≥ 20 mg/dL 1 
R – Respiratory rate ≥ 30 breaths/min 1 
В – Systolic BP < 90 mm Hg or Diastolic BP ≤ 60 mm Hg 1 
Age  ≥ 65 years 1 
 
  
ALGORITHM OF DETERMINING SEVERITY OF STATE OF 
PATIENTS WITH CAP 
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CURB-65 ALGORITHM 
0 or 1 – home treatment  
2 points – short-term hospitalization or day-patient treatment 
3 points – hospitalization 
4-5 points – hospitalization and follow-up in ICU 
It is important to emphasize that clinical judgment should be the primary 
factor while deciding on hospital admission, with the CURB-65 score providing 
assistance to this decision making (table 4). 
 
Table 5 
CURB-65 ALGORITHM 
Total 
Score 
Mortality 
% 
Risk Level Suggested Site-of-Care 
0 0.6 Low Outpatient 
1 2.7 Low Outpatient 
2 6.8 Moderate 
Short inpatient / supervised 
outpatient 
3 14.0 Moderate to High Inpatient 
4 or 5 27.8 High Inpatient / ICU 
 
Pneumonia Severity Index (table 6, 7), or PSI, is a validated risk 
stratification instrument which can help in identifying CAP patients who can safely 
be treated with antibiotics in outpatient conditions. Point values are given for a 
variety of clinical and laboratory parameters. The PSI involves calculating a score, 
which places a given patient into one of 5 risk classes. Classes I, II, and III are at 
low risk for death, and may be considered for outpatient treatment.  Risk classes IV 
and V patients should usually be hospitalized. 
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Table 6 
Scale PORT and PSI index 
Demographic factors 
Age 
Men Age (in years) 
Women Age (in years) – 10 
Nursing home resident +10 
Concomitant diseases 
Neoplastic diseases in anamnesis +30 
Liver diseases +20 
Congestive heart failure +10 
Cerebrovascular diseases +10 
Renal diseases +10 
Findings on physical examination 
Altered mental status +20 
Respiratory rate ≥ 30/min +20 
Systolic blood pressure <90 mm Hg +20 
Temperature < 35ºC or ≥ 40ºC +15 
Pulse ≥ 125 beats/min +10 
Laboratory and radiographic findings 
Arterial pH <7.35 +30 
Blood urea nitrogen >= 30/mg/dl (11 mmol/lr) +20 
Sodium < 130 mmol/l +20 
Glucose >= 250 mg/dl (14 mmol/l) +10 
Hematocrit <30% +10 
Partial pressure of arterial oxygen < 60 mm Hg or 
oxygen saturation < 90% 
+10 
Pleural effusion +10 
PORT (index PSI) Total 
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Table 7 
Stratification of Risk Score 
 
Identifying patients at high-risk for CAP mortality (who will benefit from 
intensive care unit admission): 
CURB-65 and PSI have relatively poor predictive value for identifying 
patients who will deteriorate after admission, and subsequently require transfer to 
an intensive care unit (ICU).   
Infectious Diseases Society of America (IDSA) and American Thoracic 
Society (ATS) have recently developed criteria to assist with the decision 
concerning ICU admission.  It is important to emphasize that these criteria are 
meant for guidance only, and still require prospective validation before they can be 
recommended for routine use. 
  
Risk Class PSI Points Mortality Treatment 
Low I 0-50 0.1% Outpatient 
treatment 
Low II 51-70 0.6% Outpatient 
treatment 
Low III 71-90 0.9% Short-term 
hospitalization 
Moderate IV 91-130 9.3% Hospital 
admission 
High V >131 27.0% Hospital 
admission, ICU 
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Major Criteria (1 or more = ICU admit) 
 Endotracheal intubation and mechanical ventilation 
 Shock, requiring vasopressors 
Minor Criteria (3 or more = ICU admit) 
 Respiratory rate > or = 30 min-1 
 PaO2-to-FiO2 ratio < or = 250 
 Multilobar infiltrates 
 Confusion or delirium 
 Blood urea nitrogen (BUN) > or = 20 mg/dL 
 Leukopenia (WBC count < 4000 cells/mm3) 
 Thrombocytopenia (platelet count < 100,000 cells/mm3) 
 Hypothermia (core temperature < 36oC) 
 Hypotension requiring aggressive fluid resuscitation 
Note:  These criteria await prospective validation.  Physician’s judgment 
should continue to be the primary determinant for patient admission to an intensive 
care unit. 
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Table 8 
SMART-COP 
Parameters Points 
S – systolic BP less than 90 mm Hg 2 
M – multilobar chest X-ray involvement 1 
A – albumin less than 35 g/L 1 
R – respiratory rate 25 r/min or more 1 
T – tachycardia 125 bpm or more 1 
C – confusion (acute) 1 
O – oxygen low 
PaO2 less than 70 mm Hg, or 
O2 saturation 93% or less, or 
PaO2 /FiO2 less than 333 
2 
P – pH less than 7.35 2 
Total points score (maximum 11)  
 
Interpretation of SMART-COP score 
Points Risk of need for intensive respiratory or vasopressor support (IRVS) 
0–2 low risk of need for intensive respiratory or vasopressor support (IRVS) 
3–4 moderate risk (1 in 8) of need for IRVS 
5–6 high risk (1 in 3) of need for IRVS 
> 7 very high risk (2 in 3) of need for IRVS 
Severe CAP = a SMART-COP score of 5 or more points. 
Interpretation of SMRT-CO score 
Points Risk of need for intensive respiratory or vasopressor support (IRVS) 
0 Very low risk, do not need hospitalization 
1 Low risk (1 з 20), do not need hospitalization 
2 Moderate risk (1 з 10), in-patient hospitalization 
3 High risk (1 з 6), hospitalization in intensive care 
>4 High risk (1 з 3), hospitalization in intensive care 
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Applying of these prognostic scales for evaluation of patients with CAP is 
definitely useful, as it allows to reduce the frequency of inappropriate 
hospitalization of patients with a low risk of unfavorable prognosis and select the 
category of patients who need intensive care. However, their use has some 
difficulties: first, they help to assess the severity of the patient and/or prognosis for 
a specific period of time, but they do not take into account the variability of the 
clinical picture of CAP and quick progression of the disease. Prognostic scales do 
not include such factors as decompensation of concomitant chronic diseases that 
very often are a major cause of hospitalization of patients, as well as non-medical 
indications for hospitalization. Therefore, any of prognostic scales may serve as a 
landmark only in choosing the place of treatment and in every case doctor should 
decide patient-specific.  
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Hemoglobin                                       
(m – 130–160 g/l, f – 120–140 g/l) 
Increased hemoglobin level appears in: primary and 
secondary erythremias, dehydration, burns, diarrhea, use of 
diuretics. 
Reduction in hemoglobin is observed in: anemia, acute 
bleeding, hydration, pregnancy. 
Red blood cells                                     
(m – 4,0–5,5 Т/l, f – 3,9–4,7 g/l) 
Increased level of red blood cells occurs in: primary 
erythremia, congenital heart defects, lung disease, stay in the 
highlands, renal polycystic, edema of renal pelvis, neoplasms 
(hemangioblastoma, hepatoma, pheochromocytoma), impact 
of corticosteroids, Cushing’s disease and syndrome, treatment 
with steroids . 
Reduction in: blood loss, anemia, pregnancy, rapid 
destruction of red blood cells, hydration, reduction in 
intensity of red blood cells formation in the bone marrow. 
Hematocrit                                        
(m – 40–52 %, f – 36–42%) Reduction of level in: hyperproteinemia, anemia, pregnancy, 
rapid destruction of red blood cells, hydration, reduction in 
intensity  of red blood cells formation in the bone marrow. 
Increased level in: erythrocytosis, polycythemia, congenital 
heart defects, lung diseases, stay in the highlands, kidney 
polycystic, tumors, which are accompanied by increased 
production of erythropoietin. 
The morphology of red blood cells 
Re-sizing – anisocytosis; reshaping– poikilocytosis; color 
change – anisochromia (normochromia, hyperchromia, 
normochromia). 
Color index                                        
(0,86–1,05) 
Rise of level more than 1.1 is observed in anemia (lack of 
vitamin B12, folic acid, cancer, intestinal polyps). 
Reduction of level less than 0.5-0.7 is observed in: iron 
deficiency anemia, anemia due to lead toxicity, anemia in 
pregnancy. 
COMPLETE BLOOD COUNT (CBC) INTERPRETATION ALGORITHM  
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Increase is registered in: blood loss, hemolytic anemia, on the 
background of treatment of Addison-Byrmer’s anemia with 
vitamin B12, effective treatment of anemia. 
Reduction is observed in: hypoplastic anemia, recurrence of 
Addison-Byrmer’s anemia, radiation sickness, use of 
cytostatic drugs. 
Reduction of ESR is revealed in: polycythemia, 
hyperbilirubinemia, increased levels of bile acids, erythremia 
and reactive polycythemia, hypofibrinogenemia, chronic heart 
failure. 
Acceleration of ESR is revealed in: infectious and 
inflammatory diseases (acute and chronic infections, 
pneumonia, rheumatism, myocardial infarction, syphilis, 
tuberculosis, sepsis), collagenic diseases (rheumatism, 
rheumatoid arthritis), liver damage, kidney disease, diabetes, 
thyrotoxicosis, anemia, Hodgkin's disease, multiple myeloma, 
pregnancy, postpartum period, menstruation, inflammatory 
conditions, trauma, fractures, surgery, anemia, poisoning 
(arsenic, lead), hypercholesterolemia, hyperfibrinogenemia, 
influence of drugs (morphine, dextran, methyldopa, vitamin 
D) . 
Reticulocytes                                        
(0,2–1,2 %) 
Erythrocyte sedimentation rate                                         
(m – 1–10 mm/h, f – 2–15 mm/h ) 
Platelets                                       
(180–320 G/l) 
Increased platelet count (thrombocytosis) is determined in: 
polycythemia vera, chronic myeloleukosis, blood loss, 
erythremia, metastases of malignant tumors in the bone 
marrow, after splenectomy, chronic inflammation 
(rheumatoid arthritis, tuberculosis, sarcoidosis, 
granulomatosis, colitis, enteritis), acute infections, hemolysis, 
microcytic hypochromic anemia. 
Reduction of platelet count (thrombocytopenia) is revealed 
in: leukemia, aplastic anemia, paroxysmal nocturnal 
hemoglobinuria, alcoholism, megaloblastic anemia, liver 
cirrhosis with splenomegaly, Gaucher's disease, idiopathic 
thrombocytopenic purpura, thrombocytopenia after blood 
transfusions, lymphoma, systemic lupus erythematosus, labor, 
sepsis, craniocerebral trauma, metastatic tumors, massive 
transfusion of blood and blood products. 
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White blood cells                                          
(4–9 G/l) 
Physiological increase in white blood cells count is observed 
after exercise, after meal, in premenstrual period, pregnancy 
(especially in the last months), after childbirth and 
breastfeeding, stress, after taking cold and hot baths. 
Increase of white blood cells count more than 9 g/l 
(leukocytosis) is observed in: acute inflammatory processes, 
purulent processes, infectious diseases (bacterial, fungal,, 
except for typhoid fever and epidemic typhus, measles and 
influenza), malignant neoplasmas, tissue trauma, leukemia, 
uremia, myocardial infarction, hemorrhagic stroke, bleeding, 
attacks of paroxysmal tachycardia, sepsis, major burns, 
infectious mononucleosis, diabetic coma after splenectomy. 
Physiological decrease is observed in the elderly. Decrease in 
white blood cells count less than 3 g/l (leukopenia) is in: 
aplasia and hypoplasia of bone marrow, damage to bone 
marrow with chemicals, radiation sickness, effect of ionizing 
radiation, hyperfunction of spleen, aleukemic leukemia, 
plasmacytoma, sepsis, typhoid fever, viral disease, Addison-
Byrmer’s disease, collagenic diseases, use of drugs 
(sulfonamides and certain antibiotics, NSAIDs, thyrostatics, 
antiepileptic drugs). 
Stab neutrophiles 
(1–6 %) 
Segmented neutrophiles 
 (47–72 %) 
N 
e 
u 
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Increased level of neutrophils (neutrophilia) is determined 
in: erythremia, malignant tumors, infections (bacterial: sepsis, 
septic infection, viral: herpes zoster; fungal and parasitic), 
traumatic tissue damage, myocardial infarction, pulmonary 
infarction, necrotic processes of other tissues, condition after 
blood loss, uremia, diabetic ketoacidosis, gout, eclampsia of 
pregnancy, scarlet fever. 
Reduction of neutrophils level (neutropenia) is determined 
in: aplastic anemia, agranulocytosis, viral infections 
(hepatitis, measles, rubella, influenza), fungal infections, 
histoplasmosis, toxoplasmosis, malaria, rickettsial infections, 
postinfection states, chronic bacterial infections (staph- and 
streptococcal, tuberculosis, brucellosis). 
Eosinophils                                    
(0,5–5 % or 0,02–0,3 G/l) 
Increase of eosinophils count more than 0.4 g/l (eosinophilia, 
eosinophilosis) is registered in: bronchial asthma, allergic 
skin lesions, nodular periarteriitis, eosinophilic vasculitis, hay 
fever, helminthic invasions, eczema, after introduction of 
antibiotics, in patients with decreased thyroid function, 
rheumatism, acute leukemia, parasitic infestation. 
Reduction of eosinophils level below 0.05 g/l (eosinopenia) 
is observed in: typhoid fever, dysentery, acute appendicitis, 
sepsis, traumas, burns, surgery, the first day of myocardial 
infarction, physical overload, stress. 
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Monocytes 
(3-11% or 0,09-0,6G/l  
Increased number of basophils more than 0.3 g/l (basophilic 
leukocytosis) is observed in: allergic conditions, 
polycythemia, acute leukemia, chronic myeloproliferative 
syndromes, chronic myeloid leukemia and myeloma, 
Hodgkin's disease, hemophilia, acute inflammation of the 
liver, diabetes, hypothyroidism, ulcerative intestinal 
inflammation, treatment with estrogens, prolonged exposure 
to low doses of ionizing radiation. 
Increase of monocytes level more than 1 g/l (monocytosis) is 
typical for: tuberculosis, syphilis, protozoa infections, 
monocytic and myelomonocytic leukemia, infectious 
mononucleosis, brucellosis, endocarditis, malignant tumors, 
rheumatoid arthritis, systemic lupus erythematosus, period of 
recovery after acute conditions, surgical interventions. 
Reduction of basophils less than 0.01 g/l (basonepia) is 
observed in: prolonged radiotherapy, acute infections, 
pneumonia, hyperthyroidism, stress-induced situations, in 
some cases of acute leukemia. 
Reduction of monocytes level less than 0.03 g/l is observed 
in: glucocorticoid treatment, infections with neutropenia. 
Reduction of lymphocytes level less than 1 g/l is observed in: 
pancytopenia, secondary immunodeficiency, Hodgkin's 
disease, certain liver diseases, renal failure, circulatory 
failure, malignant tumors, taking corticosteroids, severe viral 
infections. 
Increase of lymphocytes level above 4 g/L (absolute 
lymphocytosis), relative lymphocytosis – increasing in 
percentage of lymphocytes. Lymphocytosis is revealed in: 
severe physical loadings, during menstruation period, chicken 
pox, measles, rubella, whooping cough, influenza, adenovirus 
infection, acute infectious lymphocytosis, infectious 
mononucleosis, cytomegalovirus infection, tuberculosis, 
syphilis, malaria, toxoplasmosis, diphtheria, brucellosis. 
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Increase amount of urine – polyuria: diabetes mellitus and insipidus, in 
decreaseand diabetes, at decreasing of edema. Reduce of daily urine – oliguria, dehydration, diarrhea, vomiting, 
increased edema, accumulation of fluids in the cavities. 
Total amount of daily urine,  
1200-1500 ml 
Arrest of urine flow into the bladder – anuria: acute blood loss, 
persistent vomiting, acute nephritis, severe kidney diseases, obstruction 
of the ureter with calculus, compression of the ureter with tumors 
(cancer of the uterus, of uterine appendages, of the bladder). 
Retention of urine in the bladder due to inability to natural urination – 
ischuria: adenoma and prostate cancer (in men), prostatitis, urethral 
stricture, obstruction due to calculus or tumor in the bladder outlet, 
violation of the neuromuscular apparatus of the bladder in severe 
infections, intoxication after surgery and childbirth, neurological 
diseases. 
Color (light-yellow) 
Increase of intensity of urine color -  loss of fluid in edema, diarrhea, 
vomiting. 
Reddish color (meat slops) - hematuria, hemoglobinuria. 
Dark- yellow with greenish hue - presence of bile pigments in case of 
jaundice; greenish-yellow in obstructive jaundicee; greenish-brown 
(color of beer) in parenchymatous jaundice. 
Greenish-yellow – large amount of pus in urine (pyuria). 
Soot- brown - pyuria in alkaline pH. 
Dark, almost black – hemoglobinuria in hemolytic anemia. 
Whitish - plenty of phosphates (phosphaturia), lipids (lipuria). 
Red - use of antipyrine, amiopyrin, santonin. 
Pink - use of aspirin, carrots, beets. 
Brown - use of phenol, cresol, lysol, uva ursi, activated carbon 
(carbolen). 
Dark brown – use of salol, naphthol. 
ALGORITHM OF COMMON URINALYSIS EVALUATION 
URINUURINALYSISSALYSIS EVALUATIONG  
66 
 
 
 
  
Transparency 
Gravity 
(1010 - 1025) 
Turbidity due to urates presence,  disapears while heating or adding 
alkali.  
Turbidity due to phosphates presence, increases while hearting and 
disappears when adding acetic acid.  
Turbidity due to calcium oxalates presence, disappears when adding 
hydrochloric acid.  
Turbidity  caused by presence of pus, does not disappear while heating 
or adding acids or alkali. 
 
 
 
 
Increase of gravity (hyperstenuria): insufficient fluid intake, oliguria, 
loss of large amounts of fluid, diabetes. 
Reduction of gravity (hypostenuria): polyuria, prolonged fasting and 
protein-free diet, renal failure (chronic glomerulonephritis and 
nephritis), diabetes insipidus. 
рН (5–7) 
Increase of acidity occurs in: starvation, states, accompanied by fever, 
diabetes mellitus, after heavy physical loadings, tuberculosis. 
Uric acid concrement is formed at pH below 5.5; oxalate calculus - pH 
5.5-6; phosphate calculus - pH 7,0-7,8. 
In predominance of meat food –pH of urine is more acid, in vegetable 
food – urine is alkaline. 
Protein (0,002 g/l or 30-50 mg/day) 
Proteinuria is divided by the degree of severity: mild, moderate and 
severe.  
Mild (156-506 mg / day): in acute streptococcal glomerulonephritis, 
chronic glomerulonephritis, hereditary nephritis, tubulopathy, 
interstitial nephritis, obstructive uropathy.  
Moderate (500-2000 mg / day): in acute streptococcal 
glomerulonephritis, hereditary nephritis, chronic glomerulonephritis. 
Severe (more than 2000 mg / day): in amyloidosis, nephrotic syndrome. 
 
By localization, proteinuria is distinguished as following: 
Prerenal - in increased disintegration  of proteins in tissues and 
hemolysis;  
Renal - glomerular (more pronounced), tubular (less pronounced); 
Postrenal – is associated with pathology of urinary tract (ureter, 
bladder, urethra, genitals). 
  
Physiological proteinuria - temporary appearance of protein in the 
urine and occurs in muscular tension, sports, after taking cold bath or 
shower, after stresses or emotions. 
Functional proteinuria -  orthostatic proteinuria. 
Bence-Jones protein – is excreted with urine in multiple myeloma, 
Waldenstrom's macroglobulinemia. 
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Hematuria is observed in: hemorrhagic cystitis, urolithiasis (kidney 
stone, ureter stone, stone in the bladder), glomerulonephritis, acute 
pyelonephritis, tumor of kidney, bladder tumor, tumor of ureter, prostate 
cancer, renal tuberculosis, tuberculosis of bladder, trauma of genitourinary 
system, including kidney trauma, systemic lupus erythematosus, 
hypertension, circulatory failure, poisoning with: anticoagulants, toxins 
(poisonous mushrooms, snake bites), aniline, benzene, malfunction of 
blood clotting system (thrombocytopenia, hemophilia, anticoagulant 
overdose), benign familial hematuria, varicose veins of bladder neck. 
Urobilinemia is observed in: parenchymatous jaundice, hemolytic 
anemia, lead poisoning. Urobilinogen does not get in the urine in 
obstructive jaundice. 
Bile pigments (urobilinogen is 
contained in small amount and 
during tests is not detected) 
Physiological glucosuria - nutritional, during and after stress, in pregnant 
women;  
Pathological is observed in: diabetes mellitus, acute pancreatitis, 
hyperthyroidism, pheochromocytoma, acromegaly, kidney diseases with 
violation of processes of reabsorption of glucose (renal diabetes), steroid 
diabetes, brain tumors, head trauma, meningitis, encephalitis, hemorrhagic 
stroke, poisoning with morphine, strychnine, phosphorus, chloroform. 
In violation of heme synthesis, intermediate products of porphyrin ring 
synthesis and products of breakdown of hemoglobin appear in urine: 
 δ-aminolevulinic acid (2-3 mg/day);  
Porphobilinogen (up to 2 mg/day);  
Uroporphyrin (about 6 mg/day);  
Coproporphyrinogens (about 70 mg/day);  
Protoporphyrin (about 12 mg/day). 
Increasing number of these products is observed in porphyrias, which 
appear in: lead poisoning, aplastic anemia, liver cirrhosis, alcoholic 
intoxication, use of drugs (barbiturates, organic arsenic compounds). 
Bilirubinuria is observed in: obstructive jaundice, parenchymatous 
jaundice (direct (conjugated) bilirubin). 
Glucose                             
(absent or up to 0,8 mmol/l) 
Ketonuria develops in increased formation and deprivation of oxidation 
process and is observed in: decompensated diabetes, starvation, food, poor 
in carbohydrates, severe infection, comatose states, hepatorenal 
glycogenosis, increased corticosteroids level (Cushing's disease, 
corticosteroid therapy), thyrotoxicosis, cachexia, acromegaly, eclampsia. 
Erythrocytes (females – 0–3, 
males – 0–2 in the field of vision) 
In addition to glucose, other sugars in the urine can be detected: 
pentosuria - use of a large number of fruits,  
lactosuria - in nursing mothers,  
galactosuria - in galactosemia. 
Ketone bodies  
(absent or 20–50 mg/day) 
Hematuria is divided into microhematuria (urine does not change color) 
and macrohematuria (visually, urine changes its color to red).  
Unchanged erythrocytes (fresh) - contain hemoglobin and are often 
revealed in diseases of urinary tract, which led to direct vascular 
damage, cystitis, urolithiasis, urethritis  
Modified erythrocytes (lysed) – do not contain hemoglobin and are 
found in renal disease (glomerulonephritis , nephritis, pyelonephritis) 
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Depending on the degree of increase in the number of leukocytes, one 
distinguishes: insignificant leukocyturia – 8–40 in the field of vision, 
moderate leukocyturia – 50–100 in the field of vision and expressed 
leukocyturia - white blood cells cover the entire field of vision – pyuria 
(pus in the urine). 
 
 
незначна лейкоцитурія – 8-40 в полі зору 
помірна Л. – 50-100 в полі зору 
виражена Л. – лейкоцити покривають все поле зору – піурія (гній 
в сечі). 
Leukocytes (females – 0–6, males 
– 0–3 in the field of vision) 
Leukocyteuria is revealed both in inflammatory processes of urogenital 
system (pyelonephritis, cystitis, urethritis, prostatitis, vesiculitis, renal 
tuberculosis) and in non-infectious ones (glomerulonephritis, interstitial 
nephritis). 
If on the background of the increased number of leukocytes bacteriuria is 
absent, it is sterile luekocyturia. This picture may be associated with 
non-infectious diseases of urinary tract, or there is a bacterial process in 
which the agent is not detected by clinical analysis of urine or by 
standard bacteriological study (genitourinary tuberculosis, chlamydiosis, 
mycoplasmosis, ureaplasmosis). 
 
 
Erythrocytes (females – 0–3, 
males – 0–2 in the field of vision) 
 
In some cases urocytogramma is performed, it shows exactly what white 
blood cells are present in urine, determines the nature of process, which 
caused leucocyturia:  
neutrophils – pyelonephritis, cystitis, urethritis, tuberculosis, prostatitis 
mononuclear cells - glomerulonephritis, interstitial nephritis 
lymphocytes – systemic lupus erythematosus, rheumatoid arthritis 
eosinophils – allergic cystitis, allergic nephritis. 
Squamous epithelium (0–3), 
transitional (single ones in the 
field of vision), renal (not 
detected) 
Squamous epithelium - lines the urethra – its number increases in 
inflammation of the urethra (urethritis). 
Transitional epithelium - lines bladder, ureters, pelvis - increases in 
urine in inflammatory processes and tumors of the relevant localization 
(cystitis, bladder tumor, ureteral tumor, pelvic tumor, renal calculi). 
Renal epithelium - lines kidney tubules - appears in urine in lesions of 
renal parenchyma (pyelonephritis, glomerulonephritis, tubular necrosis, 
taking of salicylates, cortisol, heavy metals poisoning). 
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Cylinders (not detected) 
Cylindruria indicates various kidney damages.  
Hyaline cylinders have protein structure. Hyaline cylinders appear on 
the background of diseases which are accompanied by renal proteinuria 
(glomerulonephritis, interstitial nephritis, pyelonephritis). Also, this type 
of cylinders may appear on physical exertion, orthostatic proteinuria, 
fever. 
Granular cylinders – cast of kidney tubule, consisting of protein, rolled 
in acidic urine, on the surface of which burned-out cells of epithelial 
tubules have stuck. As a result, they get granular appearance, and their 
color is darker as compared to hyaline cylinders. Granular cylinders. 
appear on the background of diseases which are accompanied by renal 
tubular lesions and proteinuria (protein in urine), chronic 
glomerulonephritis, renal amyloidosis, diabetic nephropathy, 
pyelonephritis, viral diseases, accompanied by fever. 
Waxy cylinders – casts of distal renal tubules, consisting of dead 
epithelial cells. In appearance they are shorter and wider than hyaline 
and granular, and in their structureless mass they resemble wax. 
Formation of waxy cylinders occurs in severe acute kidney diseases 
(malignant glomerulonephritis, which makes rapid progress), or in some 
lesions of renal tissue. Thus, appearance of waxy cylinders in urine is an 
unfavorable sign. 
Leukocyte cylinders – are made up of protein and leukocytes. Their 
appearance is typical for pyelonephritis. 
Erythrocyte cylinders – are made up of protein and red blood cells and 
are characteristic for diseases, accompanied with hematuria; acute 
glomerulonephritis, renal tumor, renal infarction, renal veins thrombosis, 
high blood pressure ... 
Pigment cylinders – contain pigment (hemoglobin, myoglobin) and 
appear in diseases accompanied by hemoglobinuria. Pigment cylinders 
have brown color.  
Epithelial cylinders - consist of desquamated epithelium, are 
determined in glomerulonephritis, nephrotic syndrome. 
Bacteria (not detected) 
In a healthy person urine, which is formed in kidneys and collected in 
bladder is sterile. However even in the norm, during laboratory 
diagnostics a small number of bacteria in urine may be revealed, they are 
admixed when urine passes through the urethra. So, in clinical urinalysis 
a small number of bacteria can normally be detected, and during 
bacteriological study – up to 100 000/ml. 
Increased number of bacteria in urine - bacteriuria - indicates to a 
possible presence of inflammation in the genitourinary system: 
pyelonephritis, cystitis, urethritis, prostatitis, vesiculitis. There are 
several ways of pathogen penetration into urinary tract: 
Descending route – in infectious lesions of the kidney 
Ascending route – infectious agent enters urinary tract through the 
urethra. This variant of infection is more typical for women due to 
anatomical peculiarities (short and wide urethra). In addition, this 
mechanism of penetration of bacteria into the urine is very likely in such 
instrumental manipulations as bladder catheterization, urethroscopy, 
cystoscopy, bouginage of urethra, transurethral surgeries). 
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Hematogenous route – pathogen enters in the urinary tract with blood 
from distant foci of infection. 
Lymphogenous route of transmission is through lymphatic ways from 
infectious foci, close to genitourinary system. 
One distinguishes true bacteriuria (bacteria live and multiply in the 
urine) and false bacteriuria (bacteria penetrate in urine with blood from 
distant foci of infection, do not multiply). 
It should be remembered that bacteria in the urine may change its pH 
(acid-base properties of urine) both in one way and another. In addition, 
severe bacteriuria may lead to reduced transparency of urine – turbid 
urine. 
Bacteria (not detected) 
Inflammatory processes (pyelonephritis, cystitis, urethritis, prostatitis) 
and tumors of the urinary tract may be accompanied by increased 
mucus secretion. In this case mucous appears in clinical urinalysis. 
Another possible cause of mucus in the urine is the lack of hygiene of 
genitals before collecting material for analysis. The source of mucus in 
this case may be vaginal discharge or content from the foreskin of the 
penis (especially in case of balanopostitis). 
Mucus (not detected) 
Yeast fungi (not detected) 
However, in some states in clinical urinalysis yeast fungi, mold fungi or 
Actinomyces may be detected. Certain conditions are required for their 
appearance in urine: primary and secondary immunodeficiency 
(including patients receiving immunosuppressors and AIDS patients), 
inappropriate antibiotic therapy, various pathological processes in the 
urinary tract (pyelonephritis, cystitis, urethritis). 
More often fungi of Candida genus are detected in urine. Mold fungi 
and Actinomyces are detected rarely. 
 
Salt crystals (small amount) 
Colloid system of urine in a healthy person is able to prevent salts 
precipitation, even in significant increase of their usual concentration. 
Common causes for which salt crystals may be formed in urine: 
- Violation of colloid properties of urine: genetic predisposition, kidney 
diseases, involving violation of their function, poor blood circulation in 
the kidney; 
- Increase of salt concentration in urine: intake of large amounts of food 
rich in protein, dehydration (causes concentration of urine),  metabolic 
disorders (urine acid diathesis, gout, oxalosis, Wilson's disease, 
xanthinuria). 
Precipitation of salt crystals on the one hand may indicate to possible 
presence of kidney disease or metabolic disorders, on the other - is one 
of lithogenesis stage. 
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RULES OF URINE SAMPLING FOR DIFFERENT ANALYSES 
Universal terms for urine sampling 
Before sampling of urine, toilet of external genital organs should be 
performed. It is forbidden to collect urine during menstruation period, because the 
discharge from the genitals may get into urine. 
Collection of urine is carried out at unforced urination, the urine is collected 
into to dry, clean, colorless containers (container does not touch the body), closed 
tightly. You cannot take urine from a bedpan or pot. 
After cystoscopy it is possible to collect urine not earlier than in 5-7 days. 
Collected urine should be immediately transported to the laboratory.  
It is acceptable to storage urine in the refrigerator (temperature from +2 to +4 ° C) 
but not longer than 1.5 hour. 
Common Urinalysis 
The first portion of morning urine is taken for the analysis (last urination 
should be not later than at 2 a.m.). 
It is necessary to shake the sample and pour it into the container for urine 
with sealed lid in a volume up to 100 ml. 
  
Salt crystals (small amount) 
Salts of uric acid – urates, concentrated urine, acidic urine, urine acid 
diathesis, gout, necrotic processes in the body.  
Amorphous phosphates: alkaline urine, Fanconi’s syndrome, 
hyperfunction of parathyroid gland. 
Oxalates – salt of oxalic acid: intake of food, containing large amounts 
of oxalic acid (cabbage, potato, tomatoes, asparagus, sorrel, spinach, 
oranges, apples), oxalosis. 
Phosphate of lime: arthropathia of rheumatoid origin (arthritis, 
arthrosis), iron deficiency 
Cystine: cystinosis, liver diseases (viral hepatitis, cirrhosis), Wilson's 
disease 
Xanthine: xanthinuria 
Salts of hippuric acid: intake of food containing large amount of 
benzoic acid – blueberries, cranberries, putrid processes in the intestine. 
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Analysis of urine by Nechyporenko 
Collection of morning urine is carried out by the method of "three glass test" 
– the patient begins urination in the first glass, continues in the second, finishes in 
the third. By the volume, the second portion should be the largest. Second portion 
of urine (15-20 ml) is analyzed. 
Analysis of urine by Zimnitskiy 
At 6 a.m. a patient empties the bladder (this portion is poured out). 
Then every 3 hours (from 9 a.m. to 6 a.m. of the next morning) 8 urine 
portions should be collected in clean, dry containers with volume of 250-500 ml. If 
the patient cannot hold urine for 3 hours, he/she collects urine during these three 
hours in one container. On every glass time of collecting urine is indicated. 
All portions are stored at room temperature and all portions are delivered to 
the laboratory. 
The test is carried out at the usual drinking regimen (up to 2 liters). 
Analysis of daily urine 
The patient collects urine during 24 hours, preserving the usual drinking 
regimen (1.5-2 liters). 
At about 6-8 a.m. the patient empties the bladder, all urine is poured out. 
Then all urine is collected in a clean dark glass container, which has a wide neck 
(with a capacity not less than 2 liters). The last portion of urine is taken at the same 
time, when urine collection was started the day before (start time and end time is 
indicated). 
Container with urine is stored in a cool place. 
Volume of urine is measured and recorded, after shaking, about 100 ml of 
urine is poured out and this portion is delivered to the laboratory. 
ALGORITHM OF EVALUATION OF URINANALYSIS BY 
NECHYPORENKO 
Unlike common urinalysis, in this case quantitative indicators are calculated 
not in the field of vision but in 1 ml. 
Norm: 
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 leukocytes – in men not more than 2,000 in 1 ml, in women not more than 
4,000 ml in 1 ml; 
 erythrocytes - not more than 1,000 in 1 ml; 
 cylinders - not more than 20 in 1 ml. 
Analysis by Nechyporenko is made to reveal occult leukocyturia and 
erythrocyturia (which were not detected in common urinalysis) and to follow-up 
the effectiveness of the treatment. In addition, this analysis allows to make initial 
differential diagnosis between infectious diseases and other pathology caused by 
another factor. So if there is an overwhelming increase in the number of white 
blood cells, it is necessary to think about infectious lesions (cystitis, 
pyelonephritis), if there is a marked increase in the number of red blood cells, it is 
necessary to exclude urolithiasis (renal calculi, ureteral calculus, bladder stones), 
glomerulonephritis, neoplastic processes (tumor of the kidney, ureteral tumor, 
bladder tumor). 
ALGORITHM OF EVALUATION OF URINANALYSIS BY ZIMNITSKIY  
Evaluation of analysis results: 
 urine volume, excreted per day (first 4 portions: from 9:00 to 21:00) must 
exceed urine excreted per night (4 portions: from 21:00 to 9:00) by 2 times; 
 specific gravity should be at least 1,012-1,016 and at least one portion of it 
should be 1,017 or more; 
 low specific gravity of urine in different portions as well as reduction of 
daily fluctuations of this index indicates to decrease of concentration ability of the 
kidneys. Often, this is one of the first manifestations of kidney failure and is 
formed on the background of various kidney diseases: glomerulonephritis, chronic 
pyelonephritis, hydronephrosis, polycystic; 
 combination of low density of urine with its very small daily fluctuations 
(not more than 1003-1004) may indicates to a so-called "diabetes insipidus" - 
hormonal disease in which production of antidiuretic hormone (vasopressin) is 
reduced.  
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RULES OF BLOOD SAMPLING FOR BIOCHEMICAL ANALYSIS 
To eliminate the factors that may affect the results of the study, it is 
necessary to comply with the following rules: 
 an important condition of blood sampling for laboratory tests is fasting blood 
test performed in 8-12 hours after overnight fasting. On the day of the study it is 
acceptable to drink a small amount of water; 
 alcohol intake; smoking; fried and fatty food should be excluded preferably 
3 days before; to limit physical activity; 
 to discontinue medication, but if it is impossible - to inform laboratory 
technician; 
 if the patient cannot visit the lab in the morning, blood can be taken in the 
afternoon, after 4-6 hours’ fasting period, fatty food should be excluded from the 
breakfast. 
 
RULES OF GLUCOSE TOLERANCE TEST 
Glucose tolerance test is performed to detect diabetes and hidden carbohydrates 
metabolic disorders. The principle of the test is to measure glucose 2 times: before 
load and in 2 hours after it. 
Indications for the test are: controversial results of glucose measurement, 
incidentally revealed hyperglycemia or glucosuria and clinical signs of diabetes 
with normal glucose content. It should be noted that if the diagnosis "diabetes 
mellitus" is beyond a doubt, this test can lead to glycaemic shock development. 
Overnight fast during 8 hours (maximum 14 hours) precedes the test, patient 
may drink water. Last evening meal should contain 30-50 grams of carbohydrates. 
The patient is recommended to refrain from smoking, drinking coffee and alcohol, 
as well as from heavy physical exercise for 8 hours before the study and during it. 
PROCEDURE OF BLOOD SAMPLING AND INTERPRETATION OF DATA 
OF BIOCHEMICAL BLOOD TESTS 
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Glucose load test: 75 gr of anhydrous glucose is dissolved in 25–300 ml of 
water, patient must drink it during 3–5 minutes on an empty stomach. 
The doctor in charge and doctor-laboratory assistant should know about the 
drugs taken by the patient, which can affect the outcome of the study. If necessary, 
these drugs are discontinued (3 days before: diuretics, oral contraceptives, 
glucocorticoids). It is worth to inform the patient about symptoms of hypoglycemia 
(weakness, restlessness, irritability, hunger, sweating) if they appear, the patient 
must immediately inform the doctor. 
ALGORITHM OF EVALUATION OF GLUCOSE TOLERANCE TEST 
In case of oral glucose tolerance test the following values are base-line (in 
capillary and venous blood): 
 normal glucose tolerance is characterized by glycaemia level <6,7 mmol/l in 
2 hours after glucose load. 
 increased concentrations of plasma glucose in 2 hours after a glucose load to 
values >7,8 mmol/ (>140 mg/dl), but <11,1 mmol/l (<200 mg/dl) indicates to 
impaired glucose tolerance. 
 glucose in plasma >11,1 mmol/l (> 200 mg/dl) in venous blood in 2 hours 
after glucose load can be the basis for the preliminary diagnosis of diabetes 
melitus. 
 
ALGORITHM OF EVALUATION OF PROCALCITONIN (PCT) LEVEL  
To determine possibilities of sepsis development the following parameters 
of PCT are used: 
 PCT <0,5 ng/ml – low risk of severe sepsis and/or septic shock, it is 
recommended to repeat the measurement in 6–24 hours; 
 PCT from 0,5 to 2 ng/ml – moderate syndrome of systemic inflammatory 
response (SSIR) - "gray zone." For certain diagnosis of sepsis is impossible to 
make, it is recommended to repeat the measurement in 6–24 hours, followed by 
daily measurement; 
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 PCT> 2 and <10 ng/ml – severe SSIR, high risk of severe sepsis and/or 
septic shock, it is recommended to repeat the measurement in 6–24 hours, followed 
by daily measurement; 
 PCT> 10 ng/ml – pronounced SSIR - almost always is due to severe 
bacterial sepsis or septic shock. These levels of PCT are often associated with 
syndrome of multiple organ failure and indicate to a high risk of lethal outcome, 
daily measurements are recommended. 
To determine possibilities of acute inflammations of the lower respiratory tract 
(asthma, COPD, community acquired pneumonia) the following PCT parameters 
are used: 
 PCT <0.1 ng/ml - a very low risk of bacterial infection, administration of 
antibacterial agents is strongly not recommended, it is recommended to 
repeat the measurement in 6-24 hours; 
 PCT from 0.1 to 0.25 ng/ml - low risk, administration of antibacterial agents 
is not recommended, it is recommended to repeat the measurement in 6-24 
hours; 
 PCT from 0.25 to 0.5 ng/ml – probably a bacterial infection, antibiotics are 
recommended, the dynamics of PCT changes should be assessed; 
 PCT> 0.5 ng/ml - a high risk of bacterial infection, antibacterial agents are 
strongly recommended, the dynamics of PCT changes should be assessed. 
 
ALGORITHM OF EVALUATION OF LIPID PROFILE 
Atherogenic dyslipidemia (DL) – is the primary polygenic DL, the 
development of which is caused by the interaction of risk factors related to lifestyle 
(smoking, poor nutrition, low physical activity) and polygenic predisposition; less 
often it is monogenic hereditary DL, leading to early family atherosclerosis (AS). 
The degree of atherogenicity of lipoproteins depends on their size and 
concentration. The most atherogenic lipoproteins are low-density lipoproteins 
(LDL) and very low density (VLDL) ones. Antiatherogenic effect is produced by 
77 
 
high-density lipoproteins (HDL), which implement the reverse transport of 
cholesterol to the liver. 
Today, lipid risk factors of AS are: 
 Total cholesterol (TC)> 5,0 mmol/l; 
 LDL cholesterol > 3,0 mmol/l; 
 HDL cholesterol <1,0 mg/dl in men and <1,2 mmol/l in women; 
 Plasma triglycerides (TG)> 1,2 mmol/l; 
 The ratio of LDL/HDL cholesterol> 5 (atherogenic index). 
At the present stage to characterize violations of lipid profile, the following 
terms are used: dyslipidemia, hyperlipidemia and hyperlipoproteinemia. 
The term dyslipidemia is the broadest because it includes both increased 
levels of lipids and lipoproteins higher than the optimal value, and/or possible 
decreases of the lipid spectrum part, namely HDL or alpha-lipoproteins. 
The term hyperlipoproteinemia (HLP) means any increase in the levels of 
lipids and lipoproteins in plasma above the optimum value. 
The term hyperlipidemia is the simplest, because for its use it is enough to 
determine only increased levels of blood lipids (cholesterol and triglycerides) 
above the optimum value. 
In 1967 D.Fredrikson proposed classification of primary DL with five main 
types of DL (table 9). It is the basis of modern classification, approved by the 
WHO. 
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Table 9 
Classification of hyperlipoproteidemia 
Phenotype Cholesterol LDL ТG 
Changes of 
LP 
Atherogenic 
degree 
I Increased 
Lowered or 
normal 
Increased 
or normal 
↑ Ch 
Non-
atherogenic 
phenotype 
IIa Increased Increased Normal ↑ LDL High 
IIb 
Increased Increased Increased ↑ LDL and 
VLDL 
High 
III 
Increased Lowered or 
normal 
Increased 
↑ HDL 
High 
IV Most normal Normal Increased ↑ LDL Moderate* 
V Increased Normal 
Increased ↑ Ch and 
LDL 
Low 
Note: ↑ – increase of concentration; * – IV phenotype becomes atherogenic if it is 
accompanied by decrease in HDL cholesterol, as well as other metabolic disorders 
(hyperglycemia, insulin resistance, impaired glucose tolerance), LDL - low density 
lipoprotein; Ch - chylomicrons. 
 
It was found that the greatest risk of CHD and AS development occurs in II, 
III and IV types of hyperlipoproteidemia.  
WHO classification does not take into account the phenotype, which is 
characterized by the selective reduction of HDL cholesterol 
(hypoalphalipoproteidemia). This phenotype is more common in men and is 
accompanied by lesion of coronary and cerebral vessels. Importantly, that this 
classification precludes possiblity to diagnose the disease which caused 
dyslipidemia, but allows the physician to establish the degree of its atherogenicity. 
In the medical literature to assess the levels of lipoproteids, the classification 
of components of lipid profile, proposed in the Third report on treatment of 
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dyslipidemia in adults (Adult Treatment Panel – ATP-III) of the National 
Cholesterol Education Program of USA is commonly used (table 10). 
 
Table 10 
Classification АТР-ІІІ (2001) 
LDL cholesterol, mg / dL (mmol / L) 
< 100 (< 2,6) optimal 
100–129 (2,6–3,3) above optimal 
130–159 (3,4–4,0) extremely high 
160–189 (4,1–4,8) high 
≥ 190 ( ≥ 4,9) very high 
Total cholesterol, mg / dL (mmol / L) 
< 200 (< 5,2) preferred (normal) 
200–239 (5,2–6,1) extremely high 
≥240 (≥ 6,2) high 
HDL cholesterol, mg / dL (mmol / L) 
< 40 (< 1,0) low 
≥ 60 (≥ 1,6) high 
Triglycerides, mg / dL (mmol / L) 
<150 (< 1,7) normal 
150–199 (1,7–2,2) extremely high 
200–499 (2,3–4,4) high 
≥ 500 (≥ 4,5) very high 
 
The diagnosis of dyslipidemia, hyperlipidemia and HLP is not independent, 
it must be included in the primary clinical diagnosis of cardiovascular disease. For 
a wide use in clinical diagnosis it is proposed to use a simplified version of  
dyslipidemia classification. 
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NB! When conducting data interpretation of biochemical studies, the difference in 
the reference values of the indicators provided by different laboratories should be 
taken into account and, if possible, to carry out the subsequent dynamic sudy in the 
same laboratory. 
 
  
General protein                                       
(65–85 g/l) 
Increased protein level (albuminosis) is revealed in: multiple 
myeloma, Hodgkin's disease, autoimmune diseases, 
sarcoidosis, cirrhosis without severe hepatocellular 
insufficiency (absolute); extensive burns, prolonged vomiting, 
diarrhea, diabetes insipidus, chronic nephritis, increased 
sweating, intestinal obstruction (relative). 
Reduced protein level (hypoproteinemia) is observed during 
pregnancy and lactation (physiological); starvation, 
inflammatory disorders of gastrointestinal tract, esophageal 
stricture, poisoning, hepatitis and cirrhosis of the liver, 
albuminemia, Wilson’s disease, malignant tumors, major 
burns, hyperthyroidism, after prolonged fevers, injuries, 
hydration, physical loads, increased excretion of protein with 
urine (diabetes, glomerulonephritis, nephrotic syndrome, 
long-term (chronic) diarrhea), protein displacement in "other 
areas" (pleural exudate and transsudate, ascitis), bleedings 
(absolute); water loading, arrest of urination, reduced urine 
output, massive intravenous infusion of glucose solution, 
impaired renal excretory function, increased secretion of the 
antidiuretic hormone  
Albumin                                          
(35–55 g/l) Reduced level (hypoalbuminemia) occurs in: insufficient 
entry of protein to the body (starvation, esophageal stricture 
and others); malabsorption of protein breakdown products 
through the mucous membrane of the gastrointestinal tract 
(enteritis, resection of the stomach because of stomach ulcer, 
cancer); reduced albumin synthesis (toxic damages liver, 
cirrhosis); increased loss of protein (exudate, bleeding) in the 
lumen of the intestine (in volvulus, ulcerative colitis, 
peritonitis), on the burn surface (in extensive burns), with 
urine in patients suffering from nephrotic syndrome, acute 
and chronic glomerulonephritis; in bleedings, exiting into the 
"other areas" (formation of exudate and transsudate); in the 
postoperative period. 
Increased albumin occurs very rare, more often it is caused by 
dehydration and in hemoconcentration (introduction of 
"concentrated" solutions of albumin) 
ALGORITHM OF BLOOD CHEMISTRY EVALUATION 
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С-reactive protein                                    
(5 mg/l) 
Increased fibrinogen level occurs in: various inflammatory 
processes in the vital organs: lungs (pneumonia), kidneys 
(nephrotic syndrome, acute and chronic pyelonephritis, 
glomerulonephritis, hemolytic uremic syndrome); liver; 
peritoneum (peritonitis); reactions of acute phase (fever, 
inflammation and necrotic processes, infectious diseases, 
acute myocardial infarction, trauma, burns, major surgery); 
collagenic diseases, radiation sickness, malignant tumors, 
especially of lungs; physiological increase in pregnancy and 
during menstruation period. 
Increased C-RP level is revealed in: acute inflammation, 
myocardial infarction, systemic lupus erythematosus, 
rheumatoid arthritis, infectious nonspecific arthritis, nephritis, 
Hodgkin's disease, chronic infections, tuberculosis, obesity, 
transplant rejection, smoking, metabolic syndrome, usage of 
estrogens and oral contraceptives. 
In bacterial infections it can rise to the level of 100 mg/l and 
higher, whereas in viral infections – only up to 20 mg/l. 
Fibrinogen                                       
(1,5–4,0 g/l or 5,8–11,6 mcmol/l)                                         
D-dimer 
(< 0,25 mg/l or < 0,5 mg/l FEU) 
Increased level is observed in: disseminated intravascular 
coagulation, pulmonary embolism, deep vein thrombosis, 
surgeries, sepsis and septicemia, pregnancy, eclampsia, liver 
disease, malignant neoplasms, systemic autoimmune disease, 
myocardial infarction, stroke, renal infarction, Badda-Chiari’s 
syndrome, congestive heart failure, snake bite. 
Reduced fibrinogen level is observed in: hereditary deficiency 
of fibrinogen (non- and hypofibrinogenemia), syndrome of 
disseminated intravascular coagulation, condition after 
bleeding, pregnancy, accompanied by placental abruption, 
amniotic fluid embolism, rapid labor, thrombolytic therapy, 
asparaginase therapy, leukemia, meningococcal meningitis, 
acute and chronic liver disease, prostate cancer with 
metastases, liver cirrhosis, poisoning with hepatotropic 
agents, metastatic lesions of the bone marrow, usage of 
certain medications (phenobarbital, streptokinase, urokinase). 
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Increased procalcitonin (PCT) occurs in states, associated 
with infections: sepsis with confirmed or unconfirmed 
bacterial infection; conditions, associated with sepsis, such as 
acute pancreatitis; distinct systemic infection that can occur in 
pneumonia or acute pyelonephritis; clear systemic viremia, 
fungal infections, severe malaria; pulmonary diseases: 
aspiration and ventilator-associated pneumonia; adult 
respiratory disease syndrome (ARDS); pulmonary 
neuroendocrine hyperplasia that occurs in chronic obstructive 
pulmonary disease (COPD) or chronic bronchitis associated 
with smoking; malignant tumors, medullary thyroid cancer 
(cancer of the thyroid C-cell); small-cell lung cancer; non-
small-cell lung cancer; carcinoid tumor; other neuroendocrine 
tumors (pheochromocytoma, insulinoma); breast cancer. 
Increase is not associated with infections: burns; injuries; 
sunstroke (heat stroke), first days of therapy with 
immunosupressors and other drugs that cause the release of 
inflammatory cytokines; the first 2 days of life after birth; 
prolonged or severe cardiogenic shock; heavy and prolonged 
violation of microcirculation. 
Procalcitonin                                          
(< 0,05 ng/ml) 
Serum glucose                                                    
(3,3–6,1 mmol/l) 
Increased glucose level is revealed in: diabetes mellitus, 
traumatic lesion of the central nervous system, brain tumor, 
severe liver damage, acute and chronic pancreatitis, 
pancreatic cancer, thyrotoxicosis, acromegaly, Cushing’s 
disease and syndrome, pheochromocytoma, burns, stress 
situations, excessive use of carbohydrates by patients on 
dialysis, after consuming caffeine, adrenaline, strychnine, 
narcotic agents and hypnotics (ether, opium, morphine, 
veronal, chloroform, etc.). 
Reduced glucose level is observed in: overdose of insulin and 
other oral antidiabetic drugs, starvation, hyperinsulinism, 
insulinoma, hormonal deficiency of thyroid gland 
(hypothyroidism), adrenal glands, pituitary gland; congenital 
metabolic conditions (galactosemia, fructose intolerance, 
glycogen storage diseases), toxic liver damage (poisoning 
with chloroform, salicylic acid), some kidney lesions, lesions 
of small intestine, large resection of the stomach. 
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Glycosylated hemoglobin (HbAl) 
(< 6 %) 
Increased HbAl level occurs in diabetes (5,5–8% – well 
compensated diabetes, 8–10% – quite well compensated 
diabetes, 10–12% – partly compensated diabetes, more than 
12% – uncompensated diabetes). 
Reduced HbAl level occurs in: active synthesis of 
hemoglobin, hemolysis, regeneration of erythropoiesis after 
blood loss. 
Increased ALT is observed in: viral hepatitis, toxic liver 
damage (with chloroform, pesticides, salts of heavy metals 
and organic-chlorine compounds), infectious mononucleosis, 
cholestasis, liver cirrhosis, complicated myocardial infarction, 
treatment with large doses of salicylates, prolonged use of 
fibrates, sulfonylurea drugs of the first generation . 
Increased AST level is revealed in: muscular dystrophy, 
myocardial infarction, strokes and severe tachyarrhythmias, 
acute rheumatism, cardiac surgery, angiocoronarography, 
pulmonary embolism, toxic liver damage (with chloroform, 
pesticides, salts of heavy metals, organic-chlorine 
compounds), infectious mononucleosis, cholangitis, 
compensated cirrhosis, acute alcohol poisoning, hemolytic 
syndrome, acute pancreatitis, amebiasis. 
 
Alanine aminotransferase (АlТ)  
(m – 22 U/l, f – 17 U/l) 
Aspartate transaminase (АSТ)     
(m – 18 U/l, f –15 U/l) 
γ- hlutamyl transferase (GHT)    
(m – 18 U/l, f –15 U/l) 
Increased GHT level is revealed in: mechanical and 
congestive jaundice, cholelithiasis, cholecystitis, acute viral 
chronic hepatitis, toxic liver damage and radiation, 
posthepatic cirrhosis (compensated), alcoholic cirrhosis, 
bacony liver, primary liver tumors, malignant tumors with 
metastases in the liver, acute and chronic pancreatitis, 
pancreatic cancer, chronic glomerulonephritis, renal 
amyloidosis, myocardial infarction, alcoholism, treatment 
with anti-epileptic agents, rifampicin, oral contraceptives, 
anabolic steroids, thiazide diuretics. 
Reduced GHT level is revealed in decompensated cirrhosis. 
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α- amylase                                                    
(up to 120 U/l) 
Increased amylase level is observed in: acute pancreatitis, 
exacerbation of chronic pancreatitis, mumps, inflammation of 
the pancreas on the background of perforated peptic ulcer, 
renal failure, diabetic acidosis, after using alcohol,  
introduction of epinephrine, corticosteroids, oral 
contraceptives, narcotic agents (opiates, morphine heroin, 
codeine), tetracyclines, salicylates, furosemide, methanol 
poisoning.  
Reduced amylase level is revealed in: necrosis of the 
pancreas, thyrotoxicosis, myocardial infarction. 
Creatine phosphokinase (CPK)                                                    
(m – < 80 U/l, f – < 70 U/l) 
Increased CPC is observed in: myocardial infarction, 
muscular tissue lesions (trauma, dermatomyositis, 
Duchenne’s myodystrophy, polymyositis, rheumatic heart 
disease), severe physical exertion and running, 
hypothyroidism, stroke, acute alcohol intoxication, 
schizophrenia, epilepsy, head trauma, acute radiation 
sickness. 
 
Increased LDH is revealed in: myocardial infarction, 
insufficient function of the cardiovascular and pulmonary 
systems, inflammatory diseases of the liver and kidneys, 
pneumonia, pulmonary infarction, viral hepatitis, leukemia, 
erythremia, malignant tumors, muscle damage, muscle 
atrophy. 
Increased amylase is registered in: pregnancy, liver disease 
with cholestasis, obstructive jaundice, rickets in children, 
bone disease, osteomalacia, Paget's disease, leukemia, 
inflammation of the bile duct, hepatic jaundice, liver 
cirrhosis, infectious mononucleosis, multiple myeloma, 
Hodgkin's disease with bone lesions, breast adenoma, 
malignant tumors of the ovaries, cancer of the cervix and 
endometrium, hyperparathyroidism, diffuse toxic goiter, 
limited scleroderma, sarcoidosis, exposure to drugs 
(sulfonamides, phenylbutazone, erythromycin, tetracycline, 
lincomycin, novocaine). 
Lactate dehydrogenase (LDG)                                                    
(120–240 U/l) 
Alkaline phosphatase (AP)                                                    
(20–130 U/l) Reducing of AP is revealed in: myxedema, hypothyroidism, 
senile osteoporosis, accumulation of radioactive substances in 
bones, severe anemia, slow growth in children, C 
hypovitaminosis, D hypervitaminosis. 
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Increased levels of total and indirect (free) bilirubin 
(hyperbilirubinemia) are observed in: increased degradation 
of red blood cells (acute and chronic hemolytic anemia), 
hemolytic disease of newborns, B12-deficient anemia, 
thalassemia, large hematomas. Increased direct and total 
bilirubin may be acquired and innate. Acquired lesions 
include: infectious and viral hepatitis, cirrhosis, fatty liver, 
cholelithiasis, jaundice, pancreatic cancer, drug therapy. 
Level of direct (conjugated) bilirubin increases under the 
influence of drugs which provoke cholestasis (penicillin, 
erythromycin, sulfonamides, oral contraceptives, estrogens, 
androgens, nicotinic acid). 
Total bilirubin                                                    
(3,4–20,5 mcmol/l) 
Direct bilirubin (conjugated) 
(0,86–5,3 mcmol/l) 
Increased rest nitrogen level is observed in: conditions 
associated with increased protein breakdown (malignant 
neoplasms, pulmonary tuberculosis, typhus, diphtheria, 
scarlet fever, severe pneumonia, diabetes, severe liver 
cirrhosis, acute yellow liver, peritonitis); retention of 
nitrogenous toxins in the body (acute and chronic renal failure 
and other renal diseases, violation of blood circulation due to 
weakening of cardiovascular activity); relative hyperazotemia 
due to loss of water (profuse diarrhea, increased sweating). 
Indirect bilirubin (free) (1,7–17,1 
mcmol/l) 
Rest nitrogen                                  
(14–28 mmol/l) 
Blood urea                                  
(3,5–8,3 mmol/l) 
Increased urea level is revealed in: enhanced formation due to 
protein-rich diet, excessive catabolism of protein, leukosis, 
jaundice, severe infections, burns, dysentery, shock, intestinal 
obstruction; reduced excretion with urine (acute and chronic 
renal failure, tumors of excretory tract, of prostate, 
urolithiasis, heart failure); bleeding from upper 
gastrointestinal tract; the use of drugs (sulfonamides, 
chloramphenicol, tetracycline, gentamicin, furosemide, 
dopegit, nevigramon, lasix), dehydration. 
 
Urea nitrogen                                  
(2,9–8,9 mmol/l) 
Reduced urea level is revealed in: severe liver damage 
(poisoning with phosphorus, arsenic and other hepatotropic 
agents), decompensated cirrhosis, starvation, reduced protein 
catabolism, after administration of glucose, after dialysis, 
cachexia. 
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Creatinin                                                
(m – 44–115, f – 44–97 mcmol/l) 
Increased creatinine level is observed in: acute expressed 
violations of liver function, cardiovascular insufficiency, 
inflammatory lung diseases, fever, intestinal obstruction, 
renal failure, urinary tract obturation, acromegaly, gigantism, 
diabetes mellitus, starvation, enhanced muscular work, acute 
breakdown of muscular tissue, impact of nephrotoxic drugs. 
Decreased creatinine level is observed in: fasting, pregnancy, 
prolonged use of corticosteroids. 
Sodium                                               
(130–150 mmol/l) 
Potassium                                                
(3,6–5,4 mmol/l) 
Chlorides                                             
(95–110 mmol/l) 
Reduced sodium level is observed in: insufficient sodium 
input into the body (salt-free diet), diarrhea, vomiting, 
bleeding, burns, treatment with diuretics, Addison's disease, 
removal of ascetic fluid, hyperglycemia. 
Increased sodium level is revealed in: Cushing’s syndrome 
and disease, aldosteron-producing tumors, diarrhea, vomiting, 
increased diuresis, increased sweating, diabetes insipidus, 
reduced water intake, increased salt intake, nephritis and 
nephrotic syndrome, hyperventilation, primary 
hyperaldosteronism, stenosed renal artery, uncompensated 
diabetes mellitus. 
Reduced level of potassium is observed in: insufficient  
sodium input into the body (loss of appetite, prolonged 
starvation, lack of food intake), Kon’s syndrome, Fanconi’s 
syndrome, unrestrained vomiting, prolonged profuse diarrhea, 
acute and chronic diarrhea, fistulas (stomach, intestine) after 
administration of glucose, insulin, epinephrine, ACTH, 
mineral corticoids, anorexia 
Increased level of potassium is detected in: generalized 
necrosis, intravascular hemolysis of red blood cells, tumors, 
severe traumas, starvation, tissue hypoxia, metabolic or 
respiratory acidosis, acute and chronic renal failure, oliguria 
and anuria,  massive introduction of potassium, primary and 
secondary failure of adrenal cortex, polyuria, medications 
(indomethacin, captopril, diuretic and antihypertensive drug 
therapy). 
Increased level of chlorides is revealed in: dehydration, 
hyperventilation, acute renal failure, nephropathy, 
inflammatory kidney disease, diabetes insipidus, severe 
cardiovascular insufficiency. 
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Iron                                                        
(m – 14,3–25,1 f – 10,7–21,5 
mcmol/l) 
Total transferrin                                                         
(26,85–41,17 mcmol/l) 
Chlorides                                             
(95–110 mmol/l) 
 
Reduced level of chlorides is determined in: edemas, 
excessive sweating, diarrhea, prolonged vomiting, loss of 
contents of the small intestine, pneumonia, gastric 
hypersecretion, severe infectious diseases, lactatacidosis, 
increased intake of water. 
Increased iron level is determined in: hemolytic anemia, 
hypoplastic anemia, thalassemia, pernicious anemia, B12 and 
folic deficiency anemia, use of oral contraceptives, lead 
intoxication, viral hepatitis, liver damages (acute hepatitis, 
acute hepatic necrosis, chronic cholecystitis). 
Reduced iron level is observed in: iron deficiency anemia due 
to its insufficient entry with food, gastritis with decreased 
secretion, gastric and colon tumors, gastric resection, 
inflammation, purulent septic infections, osteomyelitis, 
rheumatoid arthritis, myocardial infarction, hemosiderosis of 
internal organs, chronic renal failure, nephrotic syndrome, 
pregnancy, liver cancer, obstructive jaundice, uterine fibroids, 
bleeding, deficiency of vitamin C. 
Increased total transferrin level (total iron binding capacity of 
blood) is observed in: iron deficiency anemia, use of oral 
contraceptives, acute hepatitis and cirrhosis, long-term iron 
therapy, frequent blood transfusions, late term of pregnancy, 
excessive intake of iron into the body. 
Reduced total transferring level (total iron binding capacity of 
blood)  is observed in: reduce of  total protein in starvation, 
nephrotic syndrome, cancer and other oncologic diseases, 
chronic infections, hemosiderosis, states, accompanied by 
lack of iron in the body. 
Transferrin                                                          
(m – 23–43, f – 21–46 mcmol/l) 
Increased transferrin level is observed in: iron deficiency, 
pregnancy, blood loss. 
Reduced transferring level is observed in: inflammation, 
malignant tumors, nephrotic syndrome, hepatopathy, 
hemochromatosis, hyperchromic anemia, thalassemia. 
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Hemostatic system is a biological system (complex of cellular and humoral 
factors) that ensures preservation of sparse state of circulating blood and adequate 
blood supply to organs, as well as prevention and quick control of bleeding by 
maintaining the integrity of blood vessel walls and their rapid thrombosing in case 
of damage. 
Hemostasis is realized by the interaction of three structural and functional 
components: 
1. blood vessel wall (endothelium and subendothelial structures) 
2. blood cells (platelets) 
3. plasmatic enzyme systems (coagulation, fibrinolytic/plasmatic, kallikrein-kinin 
and complement system). 
Thus, evaluation of hemostatic system is based on the analysis of indicators: 
• vascular-platelet hemostasis, 
• plasmatic-coagulation hemostasis 
• state of fibrinolytic/anticoagulant system. 
Indicators of vascular-platelet hemostasis: 
 bleeding time (duration) – Duke’s test – duration of capillary bleeding after 
prick of fingertip with disposable lancet to a depth of 4 mm, the stop of which is 
mainly due to the presence and functional activity of platelets. Normally it lasts for 
2–5 minutes. Extension of time: thrombocytopenia, thrombocytopathy, von 
Willebrand’s disease, severe forms of disseminated intravascular coagulation 
(DIC) syndrome, severe heparinemia. 
 Index of blood clot retraction – the process of reduction, densification and 
discharge of serum with blood clot after fibrin formation under the influence of 
contractile protein which is found in platelets. Norm is 48–64%. Reducing of index 
is observed in severe thrombocytopenia and thrombasthenia. 
HEMOSTATIC SYSTEM STUDY 
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 Study of platelet aggregation function – aggregatographia with the usage of 
stimulants of aggregation (epinephrine, ADP, collagen, rystocytinum).  
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Pleural cavity is a closed space located between the surface of the lungs and 
chest with the presence of a small amount of pleural fluid (approximately 0,1–0,2 
ml/kg on each side of the chest) and protein (less than 1 g/l) to grease leaves, due 
to its presence the movements of the lungs are facilitated during inhalation and 
exhalation. Under normal conditions a stable equilibrium between the liquid 
coming into the pleural cavity and absorbed from it is present. 
Accumulation of fluid in the pleural cavity depends on changes of 
countereffort of hydrostatic and oncotic pressure (in transsudate) and changes of 
pleural membrane permeability (in exudate). The difference of gradients facilitates 
transsudation of fluid into the pleural cavity, but existing lymphatic drainage 
prevents excessive accumulation of fluid. 
The immediate causes of excessive formation/accumulation of pleural fluid: 
 increase in hydrostatic pressure in the capillaries of the parietal and visceral 
pleura; 
 violation of lymphatic drainage at different levels, which leads to increased 
osmotic pressure of the pleural fluid; 
 decrease of oncotic pressure of blood plasma; 
 increase of capillary permeability; 
 increase of the negative pressure in the pleural space; 
 violation of the integrity of pleura and/or directly adjacent large vessels, 
especially of lymphatic thoracic duct; 
 increase of protein content in the pleural cavity; 
 immunological inflammation. 
Puncture of the pleural cavity may be of therapeutic and diagnostic purpose. 
ALGORITHM OF PLEURAL EFFUSION STUDY 
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Indications for pleural puncture with diagnostic purpose: to clarify the 
nature of effusion (transsudate or exudate) whether the fluid contains blood, pus or 
lymph. 
Indications for pleural puncture with medical purpose: inflammatory 
exudates, congestive exudates, spontaneous or traumatic pneumothorax, 
hemothorax, chylothorax, empyema. 
 
PROCEDURE OF PLEUROCENTESIS PERFORMANCE 
Puncture of the pleural cavity is performed under the local anesthesia. 
Puncture site depends on the nature of the pathological process. In case of 
pneumothorax puncture is performed in frontal position in the second intercostal 
space along the mid clavicular line. In case of fluid accumulation – in the lower 
parts of the chest. 
Choice of patient’s position depends on his/her state. In severe state when 
the patient is not able to sit, it is possible to perform puncture in the recumbent 
position with the head end summed on the side. In all other cases the patient is 
sitting with the arms crossed on the chest. After defining puncture site (by using X-
ray, ultrasound or via percussion), the skin is treated with antiseptic solution. 
Puncture site should be located 2–3 cm below the level of the fluid (usually below 
the angle of the scapula), but not lower than 8th intercostal space (due to the risk of 
liver damage), at the level of the upper edge of the rib which is located below. 
Puncture should be performed by the needle with the cut being atop the rib, 
because along the lower edge of the rib the groove, containing intercostal artery 
and nerves passes. Puncture site is infiltrated with novocaine and then along the  
passage of a needle a local anesthetic is being administered. In penetration of the 
needle into the pleural cavity, feeling of gap of the needle may appear. In correct 
position of the needle, pleural fluid or air appears in the syringe, depending on the 
disease. After removal of the pathological content the needle with the syringe are 
removed and aseptic bandage is applied. After the manipulation, a radiographic 
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study of the lungs is performed to control quality of puncture and the fluid 
obtained is sent for analysis.  
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Color (straw-yellow) 
Smell (without smell) 
Transparency (full) 
Relative density (1008-1015) 
рН (norm 7,2) 
Protein, g/l 
Glucose, mmol/l 
Pleural effusion protein / plasma protein  
LDH of pleural effusion / plasma LDH 
Rivalt’s test 
Red blood cells 
White blood cells 
Lymphocytes 
Epithelium (mesothelium) 
Eosinophils 
Fungi 
Parasites 
Neutrophils 
Bacteria 
 > 1 % 
Pleural 
mesothelioma 
 
Tuberculosis 
Exudate Transsudate 
Turbid 
Acrid smell 
Different 
More than 1015 
Less than 7,2 
Less than 3,3 
More than 30 
More than 0,5 
More than 0,6 
Positive  
More than 10 G/l  
> 
1 
G/l 
Chr. exudate 
tuberculosis 
 
 
 
Empyema 
Empyema, pleural effusion 
Echinococcus, amebiasis 
Straw-colored 
Non acrid or absent 
Transparent  
Less than 1008 
More than 7,2 
More than 3,3 
Less than 15 
Less then 0,5 
Less than 0,6 
Negative 
Less than 10 G/l 
Less than 1 G/l 
Tumors 
tuberculosis 
Less than 1 % 
Pleural effusion 
Parameter and its norm 
ALGORITHM OF PLEURAL PUNCTATE ANALYSIS 
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EVALUATION ALGORITHM OF FRACTIONAL DUODENAL 
INTUBATION 
• contents of the duodenum before stimulus introduction, during  20–40 minutes 15–20 ml of golden-
yellow bile is discharged, it is transparent, pH - neutral or alkaline, density - 1003-1016, bile 
acids - 17,4–52,9 mmol /l, cholesterol - 1,3–2,9 mmol /l, bilirubin - 0,17–0,34 
• reduced amount – hyposecretion (after cholecystectomy), in excluded gallbladder, hemolytic 
jaundice); 
• intermittent discharge – hypertension of Oddi’s sphincter (duodenitis, angiocholitis, calculi, 
malignancies); 
• change of color: dark yellow - in reflux of bile of B portion and hemolytic jaundice; light yellow - 
in lesions of the liver parenchyma, viral hepatitis, cirrhosis of the liver; blood staining - in 
duodenal ulcer, major duodenal papilla tumor, hemorrhagic diathesis. 
• time before appearance of bile portion from the common bile duct (so-called portion A1) – 3–6 
minutes; 
• shortening of time – hypotonia of Oddi’s sphincter, increased pressure in the common bile duct; 
• lengthening – hypertrophy of Oddi’s sphincter, stenosis of duodenal papilla. 
• content of the common bile duct, 3–4 minutes, 3–5 ml of light yellow bile; 
• lengthening – atony of the gallbladder, its blockade of spastic or organic origin 
(gallstones). 
• during 20–30 minutes 20–50 ml of bile of olive color is discharged, alkaline pH, density 1016–
1032, content of bile acids 57,2–184,6 mmol/l, bilirubin – 6,8 mmol/l; 
• accelerated secretion – hyperkinetic dyskinesia; 
• lengthening – hypotonic dyskinesia of the gallbladder; 
• reduced amount – decrease of bladder volume in sclerotic changes, cholelithiasis; 
• absent in: obstruction of duct with stone, tumor, violation of bladder motility. rarely in 
cholecystitis; lack of bladder reflex; 
• change of color: white bile – chronic inflammation with atrophy, very dark bile - formation of 
biliary sladge biliary sludge. 
• light yellow, alkaline pH, density 1007–1011, bile acids 13–57,2 mg/dl, bilirubin 0,17–0,34 
mmol/l; 
• pale color – hepatitis, cirrhosis; dark (pleyochromic) – hemolytic jaundice; red – tumors; 
• flows permanently while probe is in; 
• absent -  in compression of common bile duct with stone or tumor or in arrest of bile secreting 
function of the liver in severe parenchymatous lesions. 
• Norm: no cellular elements! 
• mucus, catarrhal inflammation of biliary tract, duodenitis; 
• red blood cells: trauma during intubation; 
• white blood cells: may be present only in portion A, single ones in field of vision; localization of 
inflammatory process is revealed on the basis of the largest concentration in certain portion; 
• cholesterol crystals: cholelithiasis; 
• !!! in the norm bile is sterile!  
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Sputum is a pathological secretion of the lungs and airways (bronchi, 
trachea, larynx), which is discharged in expectoration. Normally, glands of the 
large bronchi and trachea constantly produce up to 100 ml of secretion a day, 
which is generally swallowed and in healthy people it is not discharged. 
Indications for sputum analysis: 
 cough with sputum discharge; 
 pneumonia; 
 bronchitis; 
 asthma; 
 COPD; 
 lung abscess; 
 TB; 
 suspicion for cancer; 
 helminthes and fungi; 
 bronchiectasis. 
Procedure of sputum collection 
The patient collects sputum in the morning on an empty stomach. 
Beforehand teeth should be brushed and mouth should be rinsed with boiled water. 
If the patient wears dentures, they should be removed. Sputum is collected into 
sterile container during attack of cough or deep forced clearing of throat. To 
facilitate the discharge of mucus it is recommended to previously perform 
inhalation of pharynx with 0,9 % solution of sodium chloride (using nebulizer) or 
to take expectorants.  
Collection of sputum for general analysis is performed irrespective of 
antibiotic treatment. Containers for sputum collection should be made of durable 
material with tightly closed lid, to prevent possible spread of infection. Containers 
should be transparent in order to assess the quantity and quality of the collected 
SPUTUM 
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sample without opening the lid. If the sputum was collected at home or if 
laboratory is located in another medical facility, transporting time should not 
exceed 2 hours from the time of collection, if it is impossible – limits of sample 
storage in the refrigerator is 8 hours at a temperature of + 4–8° C. 
If it is planned to make a bacteriological investigation of sputum, sputum 
collection should be done before antibiotics taking orally or in three weeks after 
discontinuation of antimicrobial treatment. In case of failure of administered 
antimicrobial therapy, collecting is performed as occasion requires, following the 
previously described technique.  
 
Some quantitative and macroscopic features of sputum 
Amount of sputum, depending on a pathological process can range from a 
few milliliters to several liters per day. A small amount of sputum is discharged in 
acute bronchitis, pneumonia, heart failure or at onset of asthma attack. A large 
amount of sputum is discharged in lung edema, suppurative processes in the lungs 
(in abscess, bronchiectasis, lung gangrene, in tuberculosis process, is accompanied 
by the disintegration of tissue). Changes of sputum amount can help to access the 
course of inflammatory process in the lungs. 
Color of sputum. Sputum is often colorless. Green tint may indicate joining 
of purulent inflammation, but in cases of acute bronchitis one should consider this 
issue individually. Different tints of red color indicate admixture of fresh blood 
while rusty – the traces of destruction of erythrocytes (crupous pneumonia and 
others). Grayish or blackish sputum contains coal dust and can be found in patients 
with pneumoconiosis or in smokers. Some drugs can change the color of the 
sputum (e.g. rifampicin). 
Odor. Sputum is usually odorless. Putrid smell appears in cases of 
putrefactive infection (abscess, lung gangrene, putrid bronchitis, bronchiectasis, 
lung cancer complicated with necrosis). A peculiar "fruity" odor is specific for the 
drained cyst. 
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Nature of sputum. Mucoid sputum is observed in catarrhal inflammation of 
the respiratory tract, for example, in patients with acute and chronic bronchitis or 
tracheitis. Mucopurulent sputum is observed in bronchitis, pneumonia, 
bronchiectasis, tuberculosis. Purulent sputum is typical for purulent bronchitis, 
abscess, lung actinomycosis, gangrene. Bloody sputum is discharged in lung 
infarction, tumors, lung trauma, actinomycosis and other factors of bleeding in the 
respiratory organs. 
Sputum consistency depends on the amount of phlegm and cellular 
elements, it can be liquid, thick or viscous. 
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Respiratory failure has many causes and can come on abruptly (acute 
respiratory failure)—when the underlying cause progresses rapidly—or slowly  
 
 
S 
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M 
 
 
 
 
 
Leucocytes                     
(in the field of 
vision) 
More than 25 
16-24 
Flat epithelium (in 
the field of vision) 
Less than 10  
More than 10 Saliva or contamination with it  
Sputum  
Less than 15 
Eosinophils  
Atypical cells  
клітини 
Cancer 
Acid-resistant 
bacte 
TB 
Charcot-Leyden 
crystals 
Kurshman’s spirals  
Asthma, eosinophilic 
pneumonia 
 
Bacteria  
Bronchial asthma 
Asthma, pneumonia, TB 
Neutrophils  Bacterial infection 
 Lymphocytes  TB, helminthosis 
 
Purulent sputum 
Muco-purulent sputum 
Mucous  
 
Fungi  
More than 106 CFU, 
exception for 
S. pneumoniae 105 
Less than 106 CFU, 
exception for 
S. pneumoniae 105 
 
Pneumonia, infectious 
exacerbation of COPD 
C. albicans 
A. niger, A. flavus,                        
А. fumigatus, 
A. nidulans 
Carriers of infection 
Oropharyngeal candidiasis 
Invasive fungal infections 
ALGORITHM OF SPUTUM ANALYSIS 
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Acute respiratory failure (ARF) is a syndrome with signs of maximal 
tension of compensatory mechanisms, with failure of sufficient oxygen saturation 
of organs and systems and removal of CO2. 
At pre-hospital stage patient’s state is assessed according to САВDE 
algorithm.  
САВDE
 
С –
Circulation
•evaluate color of the skin: pale, pink, blue or marble;
•evaluate temperature of the extremities: cold or worm;
•evaluate capillary filling (norm - up to 2 sec.);
•evaluate vein filling: moderately filled or suncken due to hypovolemia;
•evaluate heart rate and blood pressure;
• listen to heart sounds.
А – Airway
• identify symptoms of airway obstruction, violation of airway patency often contributes to paradoxical 
breathing and activation of additional respiratory muscles; central cyanosis is a late symptom of airway 
obstruction; in patients who are critically ill, impaired consciousness often causes airway obstruction 
(falling back of the tongue or soft palate);
• treatment of choice in these patients is therapy with high concentrations of oxygen (> 10 l / min), 
delivered trought mask with a reservoir. 
В – Breathing
• identify symptoms that may indicate respiratory failure: excessive sweating, central cyanosis, work of 
additional muscles or abdominal breathing;
•determine the frequency of breathing movements (normal 12- 20 per minute);
•evaluate the manner of breathing, depth of breaths and symmetrical movements of the chest;
•conduct percussion and auscultation of the lungs;
•pay attention to excessive filling of neck veins (e.g. in severe asthma or tense pneumothorax), the 
availability and permeability of pleural drainage, etc.;
•determine position of the trachea.
D– Disability
•assess pupils (diameter, symmetry and response to light);
•assess the state of consciousness of the patient by scale AVPU: Alert (oriented), Vocal (responds to voice), 
Pain (reacts to pain), Unresponsive (does not respond to any stimuli);
•determine the level of glucose to prevent hypoglycemia. If the glucose level is lower than 3 mmol / l, 
provide introduction of 50.0 ml of 20% glucose solution intravenously.
Е – Exposure
•collect medical history from the patient or his/her relatives;
•study patient's medical records, check vital parameters and their changes in dynamics, check the list of 
prescribed medications and find out which of them he really takes. 
ACUTE RESPIRATORY FAILURE  
algorithm of emergency care  
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Pre-hospital stage 
 
Hospital stage 
Taking into account etiopathogenetic factors! 
1 Anesthesia in cases of severe thoracic trauma or polytrauma (i.v. or i.m. 
administration of NSAIDs or narcotic analgesics); 
• ensure the supine position with maximal extension of the head and 
diverting the lower jaw forward, release the mouth from biomasses 
and introduce the air delivery pipe;  
2 Oxygen therapy by means of nasopharyngeal mask, anesthesia-respiratory 
mask or endotracheal or tracheostomy tube; 
3 Keep airways open; 
Prescribe bronchodilators and mucolytics 
4 Stimulate respiratory center 
5 Mechanical ventilation, in case of inefficient spontaneous breathing (RR 40 
or more breaths per minute) 
 
  
1
• secure airway patency;
• ensure the supine position with maximal extension of the head and 
diverting the lower jaw forward, release the mouth from biomasses and 
introduce the air delivery pipe;
2
• oxygen therapy to keep SpO2 level ≥95%
3
• provide venous access.
ALGORITHM OF THERAPEUTIC MANAGEMENT  
IN ACUTE RESPIRATORY FAILURE 
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Pre-hospital stage 
Gastrointestinal bleeding is an acute or chronic leakage of blood into the 
lumen of the gastrointestinal tract in presence of pathological processes in the 
esophagus, stomach, small or large intestine. 
First of all, the emergence of symptoms of this condition requires immediate 
emergency call. 
1 • keep patient at complete rest; 
• transfer the patient to a horizontal position; 
• apply cold (wrapped ice) on the abdomen or give the patient to drink cold 
water 
2 • ensure venous access to the cubital vein, if possible; 
• introduce i.v.calcium gluconate or chloride, 10% – 10,0; 
• introduce chloride solution of dycinone 12.5% – 5,0 and saline solution to 
restore the volume of circulating blood. 
 
  
ALGORITHM OF THERAPEUTIC MANAGEMENT  
IN ACUTE RESPIRATORY FAILURE 
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Acute hepatic colic is one of the manifestations of gallstone disease, which is 
characterized by attacks of pain in the right hypochondrium. 
First of all, appearance of these symptoms requires immediate emergency 
call. 
1 Calm the patient; 
Ensure position on the right side, previously having put a warm heating 
pad; 
2 Introduce antispasmodic (no-spa, atropine) or anesthetic agents in parenteral 
form form: 0.1% atropine - 0.5-1.0 subcutaneously or nospanum 2% – 2,0–4,0 
i./m. or analginum 50% – 2,0 i./m., baralgin – 5,0 i.m. or i.v.; 
3 Hospitalization (to decide a question on treatment tactics) 
 
 
  
  ALGORITHM OF THE FIRST AID FOR ACUTE HEPATIC 
COLIC 
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Table 10 
Differentiated approach to the treatment of patients with complicated 
hypertonic crises 
Target organs 
damage 
First line of 
treatment  
Aim of the 
therapy  
Medications of 
choice 
Medications 
strongly not 
recommended  
Acute hypertensive 
encephalopathy 
Initial BP 
level > 
140/90 
Decrease of BP 
by 25% during 8 
hours 
labetalol, 
nicardipinum, 
esmololum  
Nitroprussid, 
hydralazin 
Acute ischemic 
stroke 
In 
performing 
thrombolytic 
therapy 
SBP > 185 or 
DBP > 110 
mm Hg. 
 Decrease and 
maintenance of 
SBP < 180 and 
DBP <105 
during 24 hours 
labetalol, 
nicardipinum, 
urapidilum, 
nitropaste 
Nitroprussid 
Without 
thrombolytic 
therapy 
SBP >220 or  
DBP >120 
mm Hg. 
Decrease of 
medium BP by 
10–15% in 2–3 
hours, and by 
15-25% during 
24 hours 
labetalol, 
nicardipinum, 
urapidilum, 
nitropaste 
Nitroprussid 
Hemorrhagic stroke  SBP >180 or 
medium BP 
>130 mm 
Hg. 
If the 
intracranial 
pressure is not 
elevated (<25) – 
SBP <160 and 
medium BP<110 
during 24 hours 
If intracranial 
pressure is 
elevated (>25) – 
SBP <180 
medium BP 
<130 and 
perfusion 
pressure of the 
brain >60–80. 
Decrease of SBP 
to 140 mm Hg is 
considered safe 
labetalol, 
nicardipinum, 
urapidilum, 
esmololum 
Nitroprussid, 
hydralazin 
Subarachnoid 
hemorrhage 
SBP > 160 
mm Hg. 
Before surgery – 
decrease and 
labetalol, 
nicardipinum, 
Nitroprussid, 
hydralazin 
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Target organs 
damage 
First line of 
treatment  
Aim of the 
therapy  
Medications of 
choice 
Medications 
strongly not 
recommended  
keep SBP <140 
mm Hg. 
After surgery – 
keep level of 
SBP <200  
urapidilum  
Nimodipine to all 
patients 
Acute coronary 
syndrome  
SBP > 160 or 
DBP > 100 
mm Hg. 
Decrease 
medium BP by 
20-30 % 
Beta-blockers, 
nitroglycerin 
Nitroprussid, 
enalaprilat 
Acute left ventricular 
failure 
Initial BP 
level > 
140/90 
Decrease of 
medium BP by 
20-30 % 
Main - 
nitroglycerin/sodium 
nitroprussid + loop 
diuretics 
Alternative – 
enalaprilat, urapidil 
Esmolol, 
metoprolol, 
labetalol 
Aortic dissection SBP >120 
mm Hg. 
 
SBP from 100 to 
120 mm Hg, 
medium BP <80 
mm Hg. 
(it is desirable to 
reduce HBR<60 
per minute) 
Esmolol/labetalol/ 
metoprolol (first 
line) or dilthiasem/ 
verapamil (if ß-
bockers are 
contraindicated)      
+ 
sodium nitroprussid, 
nikardypin, 
enalaprilat, urapidil 
(second line – if ß-
bockers are 
ineffective) 
Prescribe 
vasodilators 
before ß-
blockers use 
Intra- and 
postoperative 
hypertension 
SBP or 
medium BP 
>20% form 
BP level 
before 
operation 
 
Decrease of 
DBP by 10-15% 
or to 110 mm 
Hg in 30-60 
min. In general 
decrease of 
medium BP not 
more than by 
25%. Decrease 
of BP is on the 
background of 
moderate 
infusion therapy. 
Urapidil, labetalol, 
esmolol  
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Target organs 
damage 
First line of 
treatment  
Aim of the 
therapy  
Medications of 
choice 
Medications 
strongly not 
recommended  
cardiosurgery 
- BP>140/90 
mm Hg or 
medium 
BP>105 mm 
Hg. 
Maintain SBP 
<140 or DBP 
<90 mm Hg. 
urapidil, 
nitroglycerin, 
labetalol, esmolol, 
nitroprussid 
 
 
ß-blockers are 
not 
recommended 
in concomitant 
cardiovascular 
insufficiency 
Eclampsia Seizures 
when BP ≥ 
140/90 mm 
Hg in 
pregnant or 
parturient 
Stop the  
seizures, provide 
open airways  
Magnesium sulfate ACE inhibitors 
Hyper tonus of 
sympatic system 
(pheochromocytoma/ 
intoxication with 
cocaine, 
amphetamines, etc./ 
withdrawal of 
clonidine) 
Initial BP 
level > 
140/90 mm 
Hg. 
Decrease of 
medium BP by 
20-30% 
Alpha-
adrenoblocker 
(urapidil) 
Alternative: 
nitroglycerin/ 
nitroprusside 
sodium, verapamil 
Beta-
adrenoblockers 
without 
previous 
prescription of 
alpha blockers 
 
 
 
 
Table 2 
Medications for management of uncomplicated crises 
Medication Dose and route of 
administration 
Onset of action (min) Side effects 
Nifedipine 10–20 mg orally or 
sublingually 
15–30 Headache, tachycardia, reddening, angina pectoris 
Captopril 12,5–50 mg per orally or 
sublingually 
15–45 Hypotension in patients with renin-dependent 
hypertension 
Prazosin 0,5–2 mg orally 30 Orthostatic hypotension 
Propranolol 20–80 mg orally 30–60 Bradycardia, bronchial constriction 
Dibazol 1% 3,0–5,0 i.v. or  
4,0–8,0 i.m. 
10–30 More effective in combination with other 
antihypertensive agents 
Piroksan 1% 2,0–3,0 i.m. 15–30 Orthostatic hypotension 
Diazepam 0,5% 1,0–2,0 i.m. 15–30 Dizziness, drowsiness 
Furosemide 40–120 mg orally or i.m. 5–30  Orthostatic hypotension, weakness 
Torasemide 10–100 mg orally or i.m. 5–30. Orthostatic hypotension, weakness 
Metoprolol 50–100 mg orally or 
5–10 mg i.v. slowly  
20–30 
3–5  
Bradycardia, bronchial constriction 
Clonidine 0,01 % 0,5-2,0 i.m. 0,075-
0,3 mg orally 
30–60  Dry mouth, drowsiness. Contraindicated to patients 
with A-V blockade, bradycardia 
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 Administer i.v. bolus of 40–100 ml of 40% glucose till full recovery of consciousness. As an alternative – 1 ml of glucagon 
subcutaneously or intramuscularly. 
o 
Put the patient in lateral position, release the mouth from residual food. 
In case of loss of consciousness it is not permitted to pour sweet solutions into the mouth (risk of asphyxia!). 
If after i.v. bolus of glucose the patient is still unconscious – start i.v. drop infusion of 5 or 10% of glucose and as soon as 
possible transfer the patient to ICU.  
If the cause of hypoglycemia is the overdose of long-acting hypoglycemic drugs, continue i.v. drop infusion of 5% or 10 % 
glucose till normalization of glycemia and full elimination of the drug from the body. 
C
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• Feeling of hunger, trembling, sweating, diplopia after excessive insulin administration or oral 
hypoglycemic agents or excessive physical work, hunger. 
• Excitement that passes into coma, pulse rate – normal, rapid or slow, blood pressure – normal or 
elevated, skin – moist, tonus of eyeballs is normal or elevated, urine output – normal. 
L
a
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Hypoglycemia: plasma glucose <2.8 mmol/L. 
Hypoglycemic coma – as a rule, <2.2 mmol/L. 
Algorithm of emergency care in hypoglycemic coma 
 
  
 
 
C
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Development of collapse, signs of cardiovascular insufficiency, skin cyanosis, tachycardia, atrial fibrillation, drop of blood pressure 
(cardiovascular or collaptoid version). 
• nausea, vomiting, abdominal pain and tension of the abdominal muscles (abdominal or pseudo-peritonitis version). 
• oligoanuria with severe urinary syndrome - proteinuria, hematuria, cylinderuria, hypostenuria (renal variant). 
• clinical picture of acute stroke due to intoxication, focal symptoms, asymmetry, loss of reflexes, hemiparesis, signs of cerebral edema 
(encephalopathic version). 
L
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 Complete blood count: leukocytosis <15,000 – stress, > 15,000 – infection; 
Biochemical blood analysis: hyperglycemia, hiperketonemia, ↑ creatinine (intermittent; due to transitory “pre- renal” failure caused by 
hypovolemia), transitory ↑of transaminases and CPK, Na+ more often is normal, sometimes ↓ or ↑, K+ more often is normal, sometimes 
↓, 
• Acid-alkaline ratio (AAR): decompensated metabolic acidosis. 
Algorithm of emergency care in ketoacidotic coma 
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Insulin therapy 
Mode of small doses of 
short-acting insulin (SAI) 
i.v. bolus, then i.v. by drops, 
regarding the level of blood 
glucose. 
If glycemia is 17–39 or ↑ - 
0,1 U/kg/hr; 
If glycemia is from 11 to 17 
– 0,05 U/kg/hr; 
If glycemia is lower than 11 
– start with 4–6 U 
subcutaneously every 3-4 
hours and add 5% glucose 
solution. 
The rate of blood glucose 
decrease is not more than 4 
mmol/l /hr;  
on the first day of therapy 
do not decrease plasma 
glucose level less than 13–
15 mg/dL. 
Rehydration: 
0,9% of sodium 
chloride; 
if plasma glucose is ≤ 13 
mg/dL, 5% or 10% of 
glucose (+ 3.4 U of SAI 
for every 20 g of 
glucose); 
Rehydration rate: 1 l in 
the 1st hour, 0.5 liters - 
during 2nd and 3rd hours 
and by 0.25 liters during 
following hours. The 
total volume of infusion 
during the first 12 hours 
of treatment - not more 
than 10% of body 
weight. 
Rehydration rate is 
adjusted depending on 
CVP. If CVP <4 mm of 
water column- 
1 liter/hr., 5–12 - 0.5 
l/hr, >12 – 250–300 
ml/hr. 
Restoration of 
electrolyte imbalance 
If concentration of 
K+ is known and in 
absence of renal 
dysfunction, start i.v. 
infusion of K+ 
simultaneously with 
insulin therapy. 
If concentration of 
K+ is unknown, start 
potassium infusion not 
earlier than in an hour 
after the start of insulin 
therapy, under the 
control of ECG and 
urine output. 
Correction of 
metabolic acidosis 
Indications for 
administration of 
sodium bicarbonate: -
blood pH <7,0 or 
standard level of 
standard sodium 
bicarbonate <5 mmol/l. 
-pH 6.9 – 7,0 - 
administer 4 g of 
sodium bicarbonate 
(200 ml of 2% solution 
i.v. slowly during 1 
hour.) 
-pH is˂ 6,9 - administer 
8 g of sodium 
bicarbonate (400 ml of 
2% solution during 2 
hours). 
Without determining 
pH/AAR 
administration of 
sodium bicarbonate is 
contraindicated! 
Broad-spectrum 
antibiotics (high 
likelihood of infections 
as the cause of DKA). 
Nutrition 
After full recovery 
of consciousness,  
ability to swallow, in 
the absence of nausea 
and vomiting – small 
portions with  
additional subcutaneous 
injection of 1–2 units of 
SAI per 1 of BU. In 1–2 
days from the start of 
food intake, without 
signs of gastrointestinal 
pathology – patient can 
proceed to a normal 
diet. 
 
 
 
Algorithm of emergency care in hyperosmolar coma 
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s Polymorphic neurological symptoms (seizures, dysarthria, bilateral spontaneous nystagmus,  hyper- or hypotonia of muscles, paresis 
and paralysis, hemianopsia, vestibular disorders, etc.). Those symptoms which fail any distinct syndrome; they are variable and 
disappear when the osmolality is normalized.   
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 •Complete blood count: leukocytosis <15,000 – stress,  > 15,000 – infection;  
•Urinalysis: presence of high levels of glucose and protein (intermittent); absence of ketones; 
• Clinical blood analysis: extremely high hyperglycemia, absence of ketones, osmolarity of plasma> 320 mosml/L ,↑ creatinine 
(intermittent); the level of Na+ ↑, the level of K+ is normal, sometimes ↓, in  CRF maybe ↑. 
• AAR: no acidosis: pH> 7,3, sodium bicarbonate> 15 mmol/l, anion gap <12 mg/dL. 
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Rehydration 
In the first hour – 1liter of 0, 
9% NaCl, then – depending on 
the level of Na+: 
-in adjusted Na+>165 mmol/L: 
saline solutions are 
contraindicated. 
-in decrease of adjusted Na+ to 
<145 mmol/l switch to 0.9% 
NaCl; 
- in case of hypovolemic shock 
(blood pressure <80/50 mm 
Hg.) start with very quick 
infusion of 1 liter of 0.9% NaCl 
or colloidal solutions. 
Rehydration rate: 1st hour – 
1–1,5 liter, 2nd and 3rd hour – 
by 0,5–1 l, followed by 0,25–
0,5 l (on the background of 
controlled CVP). 
Insulin therapy 
In early stages of infusion 
therapy insulin is not 
administered or administered 
in very small doses – 0,5-2 
U/hr. i.v., maximum 4 U/h 
i.v. 
If hyperglycemia remains for 
4–5 hours, switch to insulin 
dosing regimen recommended 
for the treatment of DKA. 
Plasma glucose level should 
not be decreased faster than 
4 mmol/l/hr. and serum 
osmolarity – not more than 
by 3 mOsm/l/hr. 
Correction of electrolyte 
imbalance 
If concentration of K+ is 
known and in absence of renal 
dysfunction, start i.v. infusion of 
K+ simultaneously with insulin 
therapy. 
If concentration of K+ is 
unknown, start potassium 
infusion not earlier than in an 
hour after the start of insulin 
therapy, under the control of ECG 
and urine output. 
Broad-spectrum antibiotics 
(high likelihood of infections). 
Nutrition 
After full recovery of 
consciousness, ability to swallow, 
in the absence of nausea and 
vomiting – food intake by small 
portions with additional 
subcutaneous injection of 1-2 
units of SAI per 1 of BU. After 1-
2 days from the start of food 
intake, without signs of 
gastrointestinal pathology – 
patient can proceed to a normal 
diet. 
  
 
 
 
 
 
 
 
Algorithm of first aid in lactacidemia coma  
C
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Nausea, vomiting, muscle and chest pain, drowsiness, lethargy, Kussmaul’s breathing without smell of acetone, sharp 
decrease in blood pressure, tachycardia, oliguria or anuria,  history of treatment with biguanides combined with 
diseases that are accompanied by hypoxia.  
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• Biochemical blood test: lactate> 4,0 mmol/L, sometimes - 2,2 –4 mmol/l; any glycemia:  more often -
hyperglycemia; often– ↑ creatinine, hyperkalemia. 
• AAR: decompensated metabolic acidosis: pH <7,3,  level of serum sodium bicarbonate ≤ 18 mg/dL, anion gap 
of more than 10 mg/dL. 
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To reduce production of 
lactate: 
short-acting insulin by 2–5 
U/hr. i.v. (regimen of 
infusion is the same as in 
DKA), 5% glucose solution 
by 100–125 ml/hr. 
To remove excess of 
lactate and biguanides 
(if used): 
hemodialysis with  lactate-
free buffer; 
in acute overdose of 
metformin - activated 
carbon or another sorbent 
internally. 
To restore AAR : 
mechanical ventilation 
in  hyperventilation mode 
to eliminate the excess of 
CO2 (target: pCO2 25–30 
mm Hg.); 
administration of 
sodium bicarbonate - only 
in pH <7.0, not more than 
100 ml of 4% solution 
once, i.v. slowly, followed 
by increasing ventilation, 
to remove excess of CO2 
(produced in 
administration of sodium 
bicarbonate). 
Shock control and 
hypovolemia 
According to the general 
principles of intensive 
therapy. 
Infusion of 0,9% of NaCl 
solution i.v. at a rate of 1 
l/hr. 
                                    
 
